Dance-based avenues to advance nonpharmacologic treatment of chemotherapy effects (DAANCE): Study protocol for a multi-center, randomized controlled trial

Dance-based avenues to advance nonpharmacologic treatment of chemotherapy effects (DAANCE): Study protocol for a multi-center, randomized controlled trial | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Dance-based avenues to advance nonpharmacologic treatment of chemotherapy effects (DAANCE): Study protocol for a multi-center, randomized controlled trial Bhillie Luciani, Martha Carlson, Gretchen McNally, Madeleine E. Hackney, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6814353/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 21 Feb, 2026 Read the published version in Trials → Version 1 posted 5 You are reading this latest preprint version Abstract Background Breast cancer (BC) is among the most common forms of cancer, particularly among women. Chemotherapies that are most effective in treating BC are known to cause chemotherapy-induced neuropathy (CIN), thus leaving survivors with sensory deficits including pain, numbness, and tingling in the extremities; functional deficits such as impaired neuromotor control and motor-cognitive integration; reduced quality of life; and increased fall risk. Current pharmacologic treatments show limited efficacy and create additional unwanted side effects. In contrast, physical activity (PA) has emerged as a promising nonpharmacologic candidate for managing CIN symptoms. The purpose of this trial is to evaluate the effect of Adapted Argentine Tango (Tango) as a potential treatment for CIN. Toward this end, we will assess the intervention effect of Tango vs. the standard of care (SOC) on patient-reported outcomes of sensation, clinically-relevant measures of function, and potential mechanisms of action. We hypothesize that 4 weeks of Tango practice will improve sensation and function more than SOC among BC survivors with CIN and demonstrated balance dysfunction. Methods In a multi-center, prospective, randomized controlled clinical trial, participants are randomly assigned (1:1 ratio) to the Tango experimental or the SOC active control arms. Primary outcomes are measured from baseline to after 4 weeks of intervention in patient-reported outcomes (PROs) of sensation and dual-task function. Secondary outcomes include additional PROs, such as fatigue, and clinical measures of interest after 4 and 8 weeks of intervention and 1 month following intervention completion. Exploratory measures include postural control, gait stability, cognitive load, and blood-based biomarker concentrations. Linear mixed models will be used to model changes in PROs and function. The primary estimand will be the difference in mean change in primary outcomes from baseline to week 4 between treatment groups. Discussion The scientific premise of this study is that Tango stands to improve CIN symptoms significantly more than the current standard of care by combining PA with auditory-motor entrainment and social engagement. Our findings may lead to a safe non-pharmacologic intervention that improves CIN-related deficits. Trial Registration This trial was first posted on 12/27/24 at ClinicalTrials.gov under the identifier NCT06749210. chemotherapy-induced neuropathy oncology neurorehabilitation music dance biomechanics Figures Figure 1 Introduction Background and rationale Breast cancer (BC) is one of the most diagnosed cancers, with an estimated 2.3 million diagnoses in 2020 that disproportionately affected women ( 1 ). Of those that receive a BC diagnosis, it is estimated that 64.5% will undergo chemotherapy treatments with taxane-based agents ( 2 ) that cause secondary conditions that complicate aging, such as chemotherapy-induced neuropathy (CIN) ( 3 – 9 ). Up to 80% of breast cancer survivors who undergo chemotherapy develop CIN ( 4 , 8 ). The manifestation of CIN may cause delay or discontinuation of life-saving chemotherapy treatment and decrease quality of life ( 8 , 10 ). Symptoms include disabling pain, numbness, tingling, and/or burning in their hands and feet ( 6 , 11 , 12 ); a decrease in neuromotor control ( 13 – 16 ); deficits in motor-cognitive integration ( 17 ); and increased fall risk ( 18 , 19 ). At present, treatment options for CIN are limited ( 6 ). Despite extensive research, no pharmacologic intervention has significantly improved the neuromotor, functional, and patient-reported symptoms of chronic CIN among BC survivors. Instead, pharmacologic interventions focus on managing symptom development through nerve pain relief (e.g. gabapentin) or serotonin reuptake inhibitors (e.g. duloxetine). However, these pharmacologic solutions come with side effects, such as drowsiness and suicidal ideology. Therefore, there is a critical need to address the neurosensory motor symptoms of neuropathy created through chemotherapy treatments among BC survivors. Physical activity (PA) is a promising nonpharmacologic candidate in the treatment of CIN ( 20 – 25 ). Possible training effects of PA include reduced systemic inflammation ( 26 ), axonal regeneration in the peripheral nervous system ( 27 ), and improved executive function ( 28 ). However, additional research is needed for progressive and prescriptive exercises relevant to the resolution and/or reduction of CIN as well as to understand adherence to a program. Social dance has been proposed as a candidate PA to promote adherence ( 29 ). Social dance can be delivered as progressively challenging PA ( 30 ) that addresses functional targets of CIN such as balance and motor-cognitive integration ( 17 , 31 – 33 ), and promotes intrinsic motivation and adherence over conventional exercise programs ( 17 , 29 , 31 , 34 ). Among potential social dance forms, Adapted Argentine Tango (Tango) has been used to improve motor and cognitive impairments in Parkinson’s Disease ( 32 ), another population that experiences neuropathy and increased fall risk. As a partnered dance, Tango is a form of PA with potential to active the human dynamic system via rhythmic entrainment ( 17 , 29 , 35 ), has been associated with better intrinsic motivation to participate than traditional exercise programs ( 29 ), and may serve as rehabilitation for postural control ( 36 – 38 ), gait function ( 36 , 39 ), and patient-reported outcomes of symptoms similar to those reported by BC survivors with CIN ( 40 – 42 ). Further, pilot data show the feasibility of Tango as a potential PA-based solution for cancer survivors with CIN symptoms ( 17 , 29 , 38 ). We hypothesize that Tango will improve CIN compared to usual care. To evaluate this hypothesis, we will evaluate the effect of Tango, a light to moderate intensity social dance adapted for persons with mobility deficits ( 30 , 32 ) and breast cancer survivors ( 17 ), on patient-reported symptoms of chronic CIN, function with respect to motor-cognitive integration, and potential physiological mediators of sensation and function among BC survivors. Research by the multiple principal investigators (MPIs) established Tango as feasible for aging survivors (up to 82 years old) to engage in biweekly at a dose of 33( 4 ) (mean(SD)) min/session with high satisfaction and positive effects ( 32 , 38 ) and specifically efficacious for motor-cognitive integration in doses of approximately 20 min/class ( 17 ). We hypothesize that Tango will improve sensation, dual-task function, and their potential physiological mediators among BC survivors who demonstrate CIN with balance dysfunction. Objectives The primary objective of this experiment is to rigorously evaluate Tango as a nonpharmacologic intervention for neuropathy symptom relief – including patient-reported numbness and tingling (Aim 1 primary outcome) and dual-task function (Aim 2 primary outcome) - and to establish the first exploratory data regarding mechanisms supporting positive effects, such as change in brain activity, biomechanics, and blood-based biomarkers. We hypothesize that 4 weeks of Tango practice (2x/week; 15–30 min dose of movement-to-music per session) will improve sensation (Aim 1) and dual-task function (Aim 2) more than usual care among BC survivors with CIN and demonstrated balance dysfunction; we further hypothesize that exploratory measures will show change with 8 weeks of Tango practice. Methods Study Design This is a multi-center, prospective randomized controlled study of superiority between an experimental intervention and usual care control arm. Eligible participants who provide informed consent will be randomly assigned to the Tango experimental (EXP) or the standard of care (SOC) control group (CON) in a 1:1 ratio. The study primary endpoints are changes from baseline to 4 weeks of intervention in the patient-reported outcome (PRO) of the sensations of numbness and/or tingling (Aim 1) and the quantitative outcome of dual task function during performance of a cognitive challenge simultaneously with a walking task (Aim 2). As an exploratory endpoint, we will assess the effect of Tango on the blood-based biomarkers that potentially mediate sensation and function as well as on cognitive load during a dual-task paradigm as measured by brain activity (i.e. high gamma) (Aim 3). Tables 1 & 2 present the data collection schedule for the EXP and CON groups, formatted per the Standard Protocol Items: Recommendations for Interventions Trials (SPIRIT) recommendations (43–45). Figure 1 illustrates the overall study design as a flow diagram. As detailed in Tables 1 & 2, outcomes are assessed at the following timepoints: repeated baseline (Baseline), primary endpoint (4 weeks of intervention or SOC), 8 weeks of intervention, 12 weeks (follow-up after a 4-week period of no structured intervention being offered), and weekly for 6 months following intervention end. Secondary outcome measures include clinical and biomechanical tests of function and patient-reported outcomes that complement the primary outcome measures in addition to falls incidence. Tertiary outcome measures, listed in Table 3, include within-session effects, satisfaction collected at session end, and surveys used to inform monitoring and shaping of interventions including Rating of Perceived Exertion - Physical (RPE-P; 6–20 scale), Rating of Perceived Exertion - Mental (RPE-M; 6-20 scale), and Intrinsic Motivation Inventory (IMI). To support beneficence, individuals randomized to the control arm will be given the option of participating in the experimental intervention after primary outcomes measurement. Repeated baseline schedule Repeated baseline data have previously been collected and analyzed as described in Lantis et al., 2023 (46). Select measures (Tables 1 & 2, indicated with x † ) are collected repeatedly prior to intervention to characterize within-subject variability (WSV) in CIN-related symptoms and function at baseline. Similar to Lantis et al., 2023 (46), repeated baseline measures for postural control were achieved through collection of the postural control dynamics during silence (QEC) at the beginning of up to 3 visits, including the first screening test of postural control and 3-4 additional days. Table 1 SPIRIT report of intervention effect outcome measures for EXP group. Study Period Enrollment Allocation Post-Allocation Timepoints 3 + months post-last taxane exposure Baseline 0 EXP 4 weeks (Tango midpoint) EXP 8 weeks (Tango end) EXP 12 weeks (1-month follow up) 6-month follow up period, assessed weekly ENROLLMENT: Eligibility screen x Informed consent x Allocation x ASSESSMENTS: Adverse events (including falls) x † x x x x Neuropathy (primary outcome Aim 1) x † x x x x TUG-Cog (primary outcome Aim 2) x x x x CTCAE x † x x x Pain x † x x x Fatigue x † x x x GAD-2 x x x x PHQ-2 x x x x SF-36 x x x x Satisfaction with intervention x x Activity outside of study tracking x † x x x x Intrinsic motivation x x Postural control during silence (QEC) x † x x x Postural control during music listening (QECm) x † x x x TUG x x x x TNSr+ x x x x MiniBEST x x 6mwt (EMG, IMUs) x x Upper extremity function x x x x Goal attainment (COPM) x x x Blood-based biomarkers x x Cognitive load (EEG) x x x x † indicates a measure was repeated 3 times Table 2 SPIRIT report of intervention effect outcome measures for CON group. Study Period Enrollment Allocation Post-Allocation Timepoints 3 + months post-last taxane exposure Baseline 0 CON 4 weeks (post-SOC) CON 8 weeks (Tango midpoint) CON 12 weeks (Tango end) CON 16 weeks (1-month follow up) 6-month follow-up period, assessed weekly ENROLLMENT: Eligibility screen x Informed consent x Allocation x ASSESSMENTS: Adverse events (including falls) x † x x x x x Neuropathy (primary outcome Aim 1) x † x x x x x TUG-Cog (primary outcome Aim 2) x x x x x CTCAE x † x x x x Pain x † x x x x Fatigue x † x x x x GAD-2 x x x x x PHQ-2 x x x x x SF-36 x x x x x Satisfaction with intervention x x Activity outside of study tracking x † x x x x x Intrinsic motivation x x Postural control during silence (QEC) x † x x x x Postural control during music listening (QECm) x † x x x x TUG x x x x x TNSr+ x x x x x MiniBEST x x x 6mwt (EMG, IMUs) x x x Upper extremity function x x x x x Goal attainment (COPM) x x x x x Blood-based biomarkers x x Cognitive load (EEG) x x x x x † indicates a measure was repeated 3 times Table 3 SPIRIT report of within-session assessments. EMA refers to “Ecological Momentary Assessment” Session Type Baseline Tango Intervetion SOC (remote in MyCap app) Timepoints Before session start (Beg) Before session start (Beg) After completing session (End) Weekly ASSESSMENTS: Adverse events x a x a Neuropathy retrospective x a x a x b x a PRO-CTCAE retrospective x a x a x a Pain retrospective (24 hours) x x Fatigue retrospective (24 hours) x x Neuropathy EMA x x x CTCAE EMA x x x Pain EMA x x x Fatigue EMA x x x Postural control during silence (QEC) x x Postural control during music listening (QECm) x x Activity outside of study tracking x x x a Satisfaction with session activity as neuropathy treatment x Intrinsic motivation x c COLLECTED TO FACILITATE TRIAL MONITORING AND INTERVENTION SHAPING: Rating of perceived physical exertion (RPE-P) x b Rating of perceived mental exertion (RPE-M) x b a Recall period = during the last week, since we last saw you, OR since you last answered these questions (whichever is the shortest time period) b Recall period = during the activity just performed c Queried every 2 weeks Study setting The study is currently being conducted at The Ohio State University (OSU) in Columbus, Ohio (OH) and Yale Cancer Center in New Haven, Connecticut (CT). The research protocol has been approved by the OSU Institutional Review Board (IRB) and Yale has ceded review to this board as the single IRB for the multisite clinical trial. At OSU, participants are recruited from the Stephanie Spielman Comprehensive Breast Center (SSCBC) oncology practice as well as from the greater central OH community. At Yale, participants are recruited from the Yale Center for Breast Cancer (CBC) within the Smilow Cancer Center oncology hospital network as well as from the greater south central, CT and northern New York City, New York communities. Consent is obtained in a quiet and private setting prior to research activity either electronically, via REDCap (Research Electronic Data Capture, Nashville, TN), or using a paper version which is stored securely in a locked cabinet within a secure research-dedicated space at the host institutions. Assessments (i.e., screening, repeated baseline, midpoint, post intervention, and 1-month follow-up assessments) are performed in an outpatient care clinic setting or within the volunteer’s home environment, as preferred by the survivor. The EXP intervention is performed in a group setting of no more than 15 survivors at a time with their invited partners. The SOC portion of the CON intervention is performed by participants in their own home environment. Participants are compensated $20 per in-person assessment session that does not involve interventional instruction, with an additional $20 compensated for sessions that require sensors to be applied to the skin (potential total of up to $280 for participation in all assessments). Eligibility criteria The eligibility criteria of this study follows the criteria described in Lantis et al. (2023) (46). Briefly, participants are eligible for this study if they are 40 years old or older, diagnosed with BC (all stages), experiencing CIN (European Organization for Research and Treatment of Cancer, Chemotherapy-Induced Peripheral Neuropathy outcome measure (CIPN-20) sensorimotor score > 1 or similar on an equivalent measure), finished with taxane-based chemotherapy treatment for at least 3 months, able to understand and comply with directions associated with testing and study treatments, and if they demonstrate postural control measurements outside of normative values (47). Participants are excluded from the study if they meet any of the following criteria: pre-existing vestibular disorders, history of motor deficits or neurological disease other than CIN-related, poorly controlled diabetes (HbA1c ≥ 8.0), non-ambulatory or lower extremity amputation (Note: assistive devices allowed), participating in physical or occupational therapy during the study (Note: engagement in additional therapies or physical activities (e.g. acupuncture) will be documented), or contraindicated to participate in unsupervised activity due to other issues (e.g. herniated vertebral disc). We expect the study population to be representative of the demographics of the BC survivorship population in the United States between both sites. The CDC reports that 99% of BC cases occur among women and only 1% among men. The CDC census reports the rate of new BC cases in 2019 per 100,000 women by race as White/non-Hispanic 132.5, Black/non-Hispanic 128.4, American Indian and Alaska native/non-Hispanic 101.7, Asian and Pacific Islander/non-Hispanic 104.5, and Hispanic 101.9 (48). Recruitment and screening This research opportunity is posted on public-facing websites including ClinicalTrials.gov (NCT06749210), Research Match, and Study Search to allow volunteers to self-refer by calling a dedicated medical center phone line or emailing the secure address [email protected] . Further, advanced practice providers (APPs) refer eligible and interested clients to our research staff to complete screening. The study staff work onsite within the OSU SSCBC and Yale CBC outpatient facilities at least 2 days per week to follow up with volunteers and referring APPs. In addition, queries are run with electronic medical records (EMR) to identify potentially eligible clients of the OSU academic medical center system. Reports are generated using the criteria of a taxane-based chemotherapy plan being entered in the EMR and filtered by age (≥ 40 years) and prescribing physician. Through chart review, we identify the subset of clients who meet the study previously mentioned inclusion criteria. Researchers are provided with a list of potential recruits from a pharmacist on staff with SSCBC and Yale Cancer Center, which includes name, stage of breast cancer, whether they were exposed to taxane-based chemotherapy, and medical record number. Clinical research assistants then pre-screen participants from this list using the previously mentioned criteria. For clients that meet the inclusion criteria, we request approval from the treating oncologist to contact the client for recruitment purposes. Eligible clients who are approved for recruitment by their oncologist are contacted by phone to inquire whether CIN symptoms persist and, if so, to determine interest and availability in participating in this study. Those able and interested are asked to schedule in-person screening of postural control, which involves attempting a short, but challenging balance task reported to distinguish fallers from non-fallers by Maki et al. (1994) (49). As previously reported (50), study volunteers stand quietly and bilaterally for 30 s on a balance plate (Bertec Corp, Columbus, OH) with eyes closed (QEC). Center of pressure (COP) variables of interest are calculated per Prieto et al. (1996) (51) and Roerdink et al. (2011) (52). Survivors are offered enrollment in the study if they demonstrate QEC postural control function that is outside of the estimated 70% confidence interval (CI) (47) of healthy, age-equivalent normative values in (1) COP ellipse area, (2) medial-lateral variability, (3) medial-lateral velocity or outside of the estimated 95% CI in terms of (4) COP complexity. Values corresponding to these inclusion thresholds are >400, >4.0, >11.0, <0.6, respectively. Adequacy of the potential participant pool Between Yale and OSU, approximately 2300 new BC patients are seen annually (Yale n=1000, OSU n=1300), 500+ of whom will receive taxane-based cytotoxic chemotherapy annually. We conservatively estimate that approximately 50% of BC patients treated with cytotoxic chemotherapy will experience persistent CIN and measurable postural control deficits (Worthen-Chaudhari et al., 2018) yielding an eligible patient pool that grows by at least 113 BC survivors per site, per year. In addition to this annual presentation of new individuals with BC, both sites have established survivorship programs that serve thousands of BC survivors, including survivors not seen within our medical centers, who live with chronic CIN. Given the interest in non-pharmacologic options for survivorship treatment and lack of pharmacologic interventions to treat CIN (12), we anticipate screening 500 eligible individuals per year or 40 per month and enrolling up to 25% (i.e., 10 survivors per month) across sites. Lastly, attending classes with an invited guest (dance partner) was found to affect engagement, by improving attendance of survivors (38). Therefore, we encourage participants to invite a partner to attend training sessions with them and for those who prefer not to invite from their social circle, we provide partners from a pool of talented university students within the relevant departments (e.g. Dance, Music, Health and Rehabilitation Sciences) at both sites to activate social engagement for enrollees randomized to the Tango experimental intervention. Interventions The EXP intervention occurs over an 8-week period at a frequency of 2x per week with follow-up measures taken at 12 weeks. The CON intervention starts with 4-weeks of SOC and crosses over to experimental for the following 8 weeks at a frequency of 2x per week. No intervention session with accompanying data collection measures will last longer than 1.25 h total. Codesign of Research Study Design and Intervention Integration of patient lived experience and expertise was one of the key objectives for our group (53). Co-design is a meaningful, participatory collaborative process in research design and includes engagement of patient advocates within all stages of the research design and execution process (53). Early on in designing our interventional study, we reached out to our colleague patient advocate for input on the study planning phase. The PIs discussed the intent of the study and reached a shared collaborative understanding of the research question and how to best structure the clinical trial. Decisions at this stage were influential for all subsequent research processes. One of the central changes that occurred as a part of this discussion was shortening the waiting period from 8 weeks to 4 weeks for patients randomized to usual care. The reason for this change was based on careful deliberation of patient advocate input regarding how long survivors living with neuropathy can be expected to wait to receive potential relief through experimental intervention. Our prior work demonstrated relief from CIN dysfunction within 4 weeks of participation in the experimental intervention, therefore, we set the control wait period and primary outcome evaluation for both arms at 4 weeks (17). Experimental Intervention: Tango The Tango intervention will consist of 16 Adapted Argentine Tango (Adapted Tango) sessions over 8 weeks, adapted for individuals with mobility deficits by co-investigator (Co-I) Hackney (30,54), further adapted for survivors with BC by lead principal investigator (PI) Worthen-Chaudhari (17), and taught by PI Worthen-Chaudhari. We aim to deliver a dose of skilled movement-to-music of at least 10 min and no more than 35 min per session, with breaks for water and rest offered at least every 10 min. Recommendations for implementation of Adapted Tango as a neurologic intervention focus on prevention of falls, use of implicit learning techniques to convey skilled movement goals, the structure of class (warm-up, lesson, cooldown), scaffolding and shaping lessons over time to establish competency in fundamentals, modifications deemed necessary for specific deficits, and music selection (30,54). Each song used within this intervention is from the tango genre with a single song duration of 1.5 to 8.5 min. Participants may sit or rest as needed during or between songs. Instructors ensure appropriate activity wear choices (e.g., footwear, breast support) and ensure qualified volunteers are present to partner with participants. Instructors complete 16 h of training with Co-I Hackney as well as a certification exam to become qualified to teach the Adapted Tango technique. Volunteers who will partner participants for this study complete Co-I Hackney’s 4 h Balance Management program plus an additional 3 h of training with PI Worthen-Chaudhari during which live instruction skills are evaluated by the PI before volunteers are cleared to partner participants. The MPIs previously demonstrated that a Tango dose of about 20 minutes of movement-to-music is feasible for cancer survivors with postural control deficits to participate in at a rate of 2 times per week (17). To optimize factors mediating intrinsic motivation, instruction aims to achieve high Enjoyment and Perceived Competence among participants with low Pressure/Tension (55–57) as measured by IMI. We administer the IMI every 2 weeks to assess the achievement of these instructional goals. To assure integrity of the training, Co-I Hackney assists MPIs Worthen-Chaudhari and Lustberg to monitor fidelity of the intervention. This subset of our team – two former professional dancers turned dance scientists and one oncology practitioner – monitor participant symptoms and training progression and troubleshoot any issues that arise through regular virtual meetings. Control intervention with optional 1-way crossover: SOC with EXP The active control intervention consists of 4 weeks of SOC, as prescribed by each participant’s medical oncologist. Within SOC, medical oncologists may prescribe pharmacologic treatments such as tricyclic antidepressants, anticonvulsants, and serotonin-norepinephrine uptake prohibitors (6,8,58). They may also recommend exercise and/or physical therapy (6). During the 4 weeks, clients are asked, weekly, to document their numbness/tingling due to CIN and any adverse events that occur via a smart phone application (i.e. the MyCap version of REDCap). After completion of outcomes assessments at the primary endpoint of 4 weeks, individuals in the CON arm will have the opportunity to cross over immediately to participate in the EXP tango intervention. Procedures/plans to ensure safety of interventions Procedures to manage pain, functional guarding, inclement weather, seated interventional options and depression and anxiety monitoring are described in Lantis et al. (2023) (46). Outcome measure procedures and analysis Primary outcome measures Sensation (Aim 1): We measure the impact of Tango on sensation using patient-reported outcomes (PROs) of “numbness/tinging/burning” via a validated 11-point Likert scale (59) that queries symptom severity in the prior 7 days. All surveys are administered through OSU’s instance of the REDCap database for in-person visits and through the REDCap phone application (MyCap) for data entry that participants perform remotely (e.g., SOC activity, follow-up period). Surveys are completed by the participants themselves with no data entry from staff. Answers are reviewed manually by authorized research collaborators, who prompt participants to complete or clarify answers as needed and document their responsibility for review from a list of authorized data reviewers. Dual-task function (Aim 2): We measure function using validated clinical tests, performed in a clinical space in an area that is distraction free. The Timed Up-and-Go test (TUG) is a timed test of a person’s ability to stand from a chair, walk 10 feet (3 m), turn around, and return to sitting (60). Presence of CIN has been associated with longer TUG times (61–64). To measure dual-task function, we use the TUG performed simultaneously with a cognitive task consisting of audibly counting backward by subtracting 3 from a given number (TUG-Cog ). We previously reported that BC survivors with CIN demonstrated dual-task functional deficits with up to 78% demonstrating increased risk of falling as measured by TUG-Cog (17). Secondary and tertiary outcome measures Patient-reported outcome (PRO) survey instruments for measuring symptomatology: Patient self-report surveys data are collected as described in the Primary Outcome Measures, Sensation section above. In addition to the primary PRO-based outcome measure, we collect the following PRO measures: CIN symptoms of temperature. Self-reported sensations of “hotness” or “coldness” in the last 7 days are collected via a validated 11-point Likert scale (59). European Organization for Research and Treatment of Cancer’s Quality of Life Questionnaire, Chemotherapy-Induced Peripheral Neuropathy (CIPN-20): is a validated 20-item patient reported questionnaire instrument for longitudinal evaluation of neuropathy symptoms induced by chemotherapy for a recall period of “during the past week” (65). Other symptoms. Using the Patient-Reported Outcome version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items 39 through 56, cancer-related symptoms such as balance problems, nausea or vomiting, dizziness, sensitivity to light or noise, feeling like “in a fog”, confusion, sadness, and anxiety can be queried for the recall period of the past 7 days (66). The Brief Pain Inventory (BPI) is validated to elicit momentary (“right now”) and retrospective (prior 24 h period) self-reported pain and relevant functional capacity (67). The Brief Fatigue Inventory (BFI) is validated to elicit momentary (“right now”) and retrospective (prior 24 h period) self-reported fatigue and relevant functional capacity (68). The Short Form Health Survey (SF-36) is a quality of life (QOL) measure in cancer survivorship validated to elicit momentary and retrospective (last 4 weeks) assessment of an individuals health status. One report identified this survey as a predictive tool for assessing fall risk amongst cancer survivors (69). The Generalized Anxiety Disorder 2-Item (GAD-2) is a validated assessment of retrospective (last 2 weeks) self-reported anxiety (70). The Patient Health Questionnaire-2 (PHQ-2) is a validated assessment of retrospective (last 2 weeks) self-reported depression (Li et al., 2007). Ecological momentary assessment (EMA). EMA is a method of experience sampling that captures an individual’s self-report of their symptoms “right now” (72). We modified self-report assessments as needed to elicit self-report of symptoms “right now” at the beginning and end of intervention sessions as well as remotely through the MyCap phone application. Toward this end we used EMA items from the BPI and BFI and created EMA versions of these surveys: 11-pt Likert scale assessment of numbness and tingling in the extremities, 11-pt Likert scale of hotness and coldness in the extremities and the EORTC CIPN-20. Rather than modifying the PRO-CTCAE items 39 to 56, we used the Sports Concussion Assessment Tool symptom EMA survey of physical, cognitive, and emotional symptoms of mild brain injury which align with PRO-CTCAE items 39 to 56. Assessment during the activity just performed: Finally, to query whether symptomatology was affected by the interventional activity, we modified all PRO instruments to query for the recall period of “during the activity just performed”. Satisfaction with intervention is measured after each class using a 7pt Likert scale and prompt for feedback about what did/did not work per class. Feedback is used to improve future sessions . The Intrinsic Motivation Inventory (IMI) was developed from the perspective of Self Determination Theory to assess 7 dimensions of experience: Interest/Enjoyment, Perceived Competence, Effort/Importance, Pressure/Tension, and Choice (73). We administer the 9-item short form of the IMI monthly to optimize instruction around low Pressure/Tension and high Interest/ Enjoyment (56,57) as well as to explore relationships between adherence, motor effects, and IMI dimensions including perceived benefit (i.e., Effort/Importance). Function Activity tracking: Participants are asked if they have participated in the following activities: physical therapy, occupational therapy, fitness activity, other therapeutic or fitness activities. If any category of activity is checked as having occurred then participants are prompted to estimate the amount of time spent doing the activity since we last saw them (hours, minutes). If participants indicate that physical or occupational therapy were started during the study period, we remind them that these are an exclusion criterion and give them the choice of postponing engagement in skilled therapy until after completion of the study or termination of study participation. Falls tracking: Falling is defined as an unexpected loss of balance in which an individual comes to rest at a position lower than before the unexpected event (74). We elicit self-report of falls and loss of balance using the question “How many times have you fallen or felt like you lost your balance since we last saw you?” Responses are typed by the participant and reviewed for incidence of falls, incidence of loss of balance, and details offered about either incidence. During the 6-month follow-up period after intervention end, each participant will use the MyCap application to report falls weekly. Barriers to participation: Participants are asked “To help us understand barriers to participation, if you missed a session, please indicate the reason why you were unable to attend (e.g., schedule conflict, transportation, didn’t feel up to it, forgot).” Clinical To measure dynamic balance function , we collect Mini Balance Evaluation System Test (MiniBEST ) , which evaluates sensory organization, anticipatory and reactive postural control, and dynamic gait indices (75) was found to discriminate BC survivors from controls in at least one prior study (64), and has been recommended for use in studies of neuropathy (18). The subtasks enable calculation of postural control variables of interest for predicting fall risk. To measure walking endurance , we collect the 6-minute walk test (6mwt), which quantifies the distance an individual can walk within 6 minutes, where shorter distances correlate with poorer function including among survivors with CIN (76). Meta-analysis of 6mwt results among adults with pathology or fear of falling indicate that 14.0–30.5 m represents the minimum clinically-important difference (MCID) for improvement in this measure (77). Among BC survivors, a separate meta-analysis found that BC survivors cover less distance as compared to individuals living without cancer (78). The 6mwt is performed in a designated space within each site’s oncology clinic, in a quiet area without distractions. Participants walk in a loop with the following configuration: a straight distance of 19.8 m minimum marked by tape on the floor that participants turn around to their left; participants are cued to walk straight between tape marks and to turn comfortably at the end of each straightaway at the fastest pace they feel they can maintain for 6 min, resting as needed in a standing position before continuing. As a further measure of CIN and sensation, we will use the Total Neuropathy Score (TNS) - Revised (79) (TNSr) with the “sense of touch” section added per Streckmann et al. (2024) (80). This tool measures peripheral nerve impairments in the upper and lower extremities by evaluating symptoms, sensation, and deep tendon reflexes. In the shortened and revised TNS, subjective sensory symptom presence of tingling, numbness, and pain are evaluated in both the upper and lower extremity. Sensation of vibration is evaluated with a Rydel-Seiffert 128 Hz tuning fork on the bony processes of the upper and lower extremities from distal to proximal, while perception of touch is evaluated by stroking the upper and lower extremities. Finally, deep tendon reflexes of the upper and lower extremities are assessed from distal to proximal. Upper extremity (UE) function will be measured using the back scratch item from the Senior Fitness Test (81). Grip strength will be measured using a standardized digital hand grip dynamometer (Jamar 3-piece Dynamometer, Fabrication Enterprises, Elmsford, NY). In the rehabilitation of individuals with neuropathy, grip strength has shown to be an important clinical outcome in assessing upper extremity impairment and is an important predictor of functional status, muscular endurance, and overall strength (82–84). Participants will be seated comfortably with their elbow flexed at 90 degrees, forearm in a neutral position, and wrist in slight extension. After a demonstration and one practice attempt, each participant will perform three maximal grip efforts with a rest period of 10 seconds between trials to prevent fatigue. The maximum of the 3 trials will be used for analysis. Occupational performance : The Canadian Occupational Performance Measure (COPM) (85) will be administered through a collaborative process with each participant to identify the patient-reported 5 most important occupations related to self-care, leisure, or productivity. In a semi-structured interview with the study therapist, participants will rate their current performance and satisfaction with performance on each activity using an ordinal scale ranging from 1 to 10 points, with higher scores indicating better scores. These assessments will be conducted at baseline (pre-intervention) and repeated at the conclusion of the intervention (post-intervention) to gauge any changes in functional performance and perceived satisfaction. A change of 2 points is considered the threshold for a clinically meaningful change (85). This individualized, client-centered approach of this COPM instrument allows for precise measurement of intervention outcomes, ensuring that improvements in daily functioning are accurately captured and meaningful to the participants (86–88). Biomechanical Measures of walking variability and stability have been found indicative of mild cognitive impairment (89), age (90), fall risk (91–93), and neuropathy (94,95) regardless of age or type of cancer (96) including specifically in BC (16,94,97). Gait stability measures will be collected using inertial measurement units (IMUs) (Trigno Centro, Delsys, Natick, MA) affixed to the foot, leg, thigh, pelvis, and/or lower cervical spine during while participants perform the 6mwt (98), where foot IMU sensors will detect heel strike and toe off events within the gait cycle. The non-linear measures of local dynamic stability (99–102) and recurrent quantification analysis (RQA) (103) will also be analyzed. An IMU sensor placed on the upper torso (C7 vertebral spine) will collect gyroscopic data to detect bouts of steady-state walking behavior along a straight path within the 6mwt. Steady-state bouts of walking that are longer than 4 strides (101,104) will be used to calculate non-linear measures of gait stability. From this, mean Lyapanov exponent and RQA measures will be calculated over the course of the 6mwt. From the steady-state bouts, the coefficient of variation (CV) will also be calculated for step length, gait speed, and other measures of variability previously found sensitive to health status (91,92,105). We measure postural control through center of pressure (COP) data collected in accordance with our group’s previous studies of balance deficits (46,47,50). Data are recorded on a portable balance plate (Bertec Corporation, Columbus, OH) at while participants stand on the plate quietly with their eyes closed (QEC). The data are captured using custom software written in LabVIEW (National Instruments, Austin, TX) at a sampling frequency of 1000 Hz and consist of one channel of vertical force data (Fz) and two channels of moment data (Mx, My) over time. Additionally, we complete the QEC measure while listening to music (QECm) to examine the relationship between music listening and postural control over the course of the intervention, as it has been shown that postural control improved amongst healthy college-aged individuals after listening to music (37). We follow the same protocol listed in our group’s previous work, where a participant completes a QEC posture while listening to the musical composition "La Cumparsita" (46). From the QEC and QECm data, we calculate the COP time series for the 30-s duration of QEC condition performance. We then calculate the measures of future fall risk from the two tasks: COP variability in resultant and medial– lateral planes (RMSr, RMSml), medial-lateral sway velocity (COPv), and 95% ellipse area (COPa) for the 30-s duration per Prieto et al., (1996) (51) well as sample entropy using the increment method of calculation (SEI) (52). Co-contraction index (CCI) is the ratio of the muscle activity produced in the agonist versus the antagonist muscles of the leg, measured via electromyography (EMG), which can provide unique insights into neuropathy effects (106). For this protocol, we measure signals in the tibialis anterior, lateral gastrocnemius, and soleus muscles during performance of the 6mwt, QEC, and QECm tasks. Exploratory measures Blood-based biomarkers Blood sample data collections will occur at baseline, after 4 weeks of usual care for members of the CON group, and after 8 weeks of intervention for members of the EXP group. Blood sample collections will occur in the same facilities mentioned in the Study Setting section, during scheduled clinical or research appointments. Blood will be drawn in two 6 mL EDTA tubes at the timepoints described previously. Best practice regarding collection and centrifugation will be followed to extract the plasma layer and store aliquots (107). All cryovials containing plasma will be labeled and stored in a -80°C freezer, accessible to laboratory personnel only. Aliquots from each timepoint per participant ID will be shipped to Yale facilities for further processing on an annual basis. Blood-based biomarkers of interest include targeted indices linked to breast cancer (7,108), neurorecovery (109–111), and neurotoxicity/trauma (7,112). Panels of markers will be measured in plasma. We will investigate a battery of biomarkers using singleplex assays. We list these in order of priority for analysis below in the even that unexpected funding changes impact biomarker analysis budget: Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) (Benashley et al., 2022; Burgess et al., 2022; Rodwin et al., 2022). Interleukin-6 (IL-6), IL-10, brain-derived neurotropic factor (BDNF) (7,114), tumor necrosis factor α (TNF-α) (109,111). Other cytokine and inflammatory biomarkers associated with neurotoxicity including but not limited to: IL-7, IL-8, IL-9, interferon gamma (IFN-γ), interferon induced protein 10 (IP-10; CXCL-10), macrophage derived chemokine (MDC), monocyte chemoattractant protein 1 (MCP1; CCL-2), transforming growth factor-α (TGF-α), serum amyloid protein (SAA), endothelial markers (ICAM-1, VCAM-1) (108,109). At the baseline, after 4 weeks for the CON group, and after 8 weeks for the EXP group, we will measure NfL, a neuronal cytoskeletal protein that has indicated axonal damage in animal CIN models and survivors (7). NfL serum concentration will be assessed by ultrasensitive single molecule array (Simoa NF-Light® assay, Quanterix, Billerica, MA). We will investigate synaptic plasticity through via BDNF and GFAP, sampled at baseline, after 4 weeks for the CON group, and after 8 weeks for the EXP group. BDNF levels will be analyzed at the Yale facility, while GFAP levels will be assessed by the Quanterix laboratory (Quanterix, Billerica, MA). Cognitive load Brain activity will be collected via electroencephalography (EEG) and occur at baseline, after 4 weeks of SOC or INT, and after 8 weeks of intervention. EEG data collection will occur in the same facilities mentioned in the Study Setting section, using a mobile EEG system (eego, ANT Neuro, Netherlands) with 24-channels (waveguard net, ANT Neuro, Netherlands), sampling at a frequency of 2048 Hz. EEG signal processing and analysis will follow Crasta et al. (2018) (115) using BV Analyzer (Brain Vision LLC, Garner, NC) to extract mean activity per frequency band, phase synchrony, and event-related potentials. The protocol to assess cognitive load follows that of Worthen-Chaudhari et el., 2024 (17). EEG signals were collected during the performance of the following postural and motor-cognitive tasks. Conditions listed in Table 4 below are completed by each participant while standing with their shoes off, feet 7 cm apart from the inside of their feet, hands to their side, and facing comfortably straight ahead. Participants will be guarded by trained research staff during standing tasks and will get a break at the halfway mark of each task. Each task lasts for 3 minutes. Auditory stimuli will be presented through ER-3A-inserted earphones (Etymotic Research, Elk Grove Village, IL) via a custom-made program in PsychoPy (Open Science Tools, Nottingham, England). Table 4: EEG conditions Condition Description Seated, eyes open Resting data collected while seated. Participants will be instructed to watch a fixation point on a screen in front of them. Quiet standing, eyes open Participants will be instructed to stand with their eyes open while viewing a fixation point on a screen in front of them. Quiet standing, eyes closed Participants will be instructed to stand with their eyes closed. Standing, eyes open with music Participants will be instructed to stand while Tango music is played. They will be instructed to watch a fixation point on a screen in front of them. Standing, eyes closed with music Participants will be instructed to stand with their eyes closed while Tango music is played. Visual oddball While standing, participants will be instructed to mentally count how many odd stimuli (yellow square in the center of the screen) are present while ignoring the repetitive stimuli (red square in the center of the screen). Auditory oddball While standing, participants will be instructed to mentally count the oddball tone (1500 Hz) and ignore the standard tone (1000 Hz). For the visual and auditory oddball, each stimulus is presented for 500 ms with a random inter-stimulus interval from 500 ms to 1 second. A total of 100 stimuli are presented (80 standard and 20 oddball). Within-session effect At the beginning and end of each in-person intervention session, we collect a subset of PRO data with which to evaluate the effect of the session (Table 3). Each PRO measurement is collected from participants using a computer, a touch screen tablet, or a cell phone. Power calculations Allowing for up to approximately 30% loss to follow-up, we plan to enroll 70 subjects per arm to retain 50 per arm per site. This drop-out rate is conservative, corresponding to criteria that we used previously to assess an intervention’s feasibility (38,116). We use a two-sample t-test 5% significance level (two-sided) as a conservative approximation to our analysis procedure. Due to additional covariate information and early information from subjects lost to follow-up, we expect greater power from our linear mixed model analysis. To calculate effect size of the Aim 1 primary outcome measure: CIN sensation, we used the Numbness and Tingling (NT) 11-point scale (i.e., 0–10) from a study of physical activity for CIN among MBC survivors that observed post-chemotherapy scores with a standard deviation of 2.5 in the control arm and 1.9 in the treatment arm (Kleckner et al., 2018). Using the same standard deviations we have approximately 80% power to detect a minimum clinically significant difference of 1.25 (corresponding to minimally clinically important difference of 2.5 points on the 0–20 CIN-20 5-item sensory scale). To calculate effect size of the Aim 2 primary outcome measure: dual-task function in the motor and cognitive domains, we used an effect size of 0.56 (Cohen’s d ) based on preliminary data from 14 BC survivors with CIN participating in our pilot work (R21-AG068831); the effect size was verified as a conservative estimate as compared to a later calculation using a larger cohort of 46 BC survivors with CIN (17). Enrolling 70 participants per group (140 total) allows for a drop-out rate of up to 30% to yield full follow-up on 50 participants per arm and 80% power to detect the target effect size at the 5% significance level. This drop-out rate is conservative, corresponding to the criteria that we previously used to assess an intervention’s feasibility (38,116). Randomization After a participant has qualified, consented to participate in this trial, and completed repeated baseline testing, researchers randomize them 1:1 into one of two groups: EXP or CON. Randomization is blocked and stratified by site, age (≥61 vs <61), baseline CIN sensation (Likert ≥4 vs <4), and baseline functional status (TUG-Cog ≥12.64 s vs <12.64 s) based on the results of previous work in our lab (17). CIN sensation was identified through the 11-point Likert scale (59) administered during the repeated baseline period. Functional status is identified by averaging the times of 3 TUG-Cog trials that participants completed during the repeated baseline period. Randomization is accomplished using a schedule that was generated by the statistician prior to the trial opening to enrollment. The clinical research coordinator will assign allocation and enroll participants. One member of the research team is blinded to the randomization schedule prior to allocation; this researcher administers TUG and TUG-Cog to participants throughout the study. Study participants cannot be blinded; they will inevitably know their group assignment as they are participating in a distinct intervention in comparison to usual care. Data management Each study participant is assigned a unique six-digit identification number that cannot be traced to their protected health information. Participant data, coded using these identification numbers, are stored in a central database using REDCap. REDCap is a secure web-based platform that is designed for clinical trials which meets both HIPAA and 21 CFR. Clinical and biomechanical data are collected by study staff who input results into REDCap manually or via data upload. PRO data is manually entered into REDCap by study participants: participants undergoing the Tango intervention fill out questionnaires within REDCap before the start and at the end of each Tango session. SOC participants fill out questionnaires within MyCap, a mobile device application of REDCap once per week during the SOC wit period, for the purpose of adverse events reporting and symptoms tracking, then transition into the Tango intervention protocol in which they fill out questionnaires within REDCap before the start and end of each Tango session. Statistical analysis All outcome analyses will be performed on an intent-to-treat basis, and all hypothesis tests will be two-sided and at the 5% significance level or 95% confidence level. Longitudinal linear mixed models will be used to model changes in PROs and dual-task function. Fixed effects will be included for condition, session number within condition, baseline outcome measure, age, diabetes status, physical fitness activity (defined by weekly duration and metabolic equivalents), and number of previous chemotherapy lines. Random effects for subjects and study center will be used to account for within-subject and within-center correlation, and covariance estimated by restricted maximum likelihood. Exploratory Aim 3 will be assessed via causal mediation analysis using marginal structural models. The primary estimand will be the contrast representing the difference in mean change in outcome measure from baseline to week 4 (end of randomized treatment comparison) between treatment groups. While we expect balance between groups due to randomization, we will adjust for potential confounders including age, body mass index, concurrent medications, and other variables if an imbalance between groups occurs by chance. Pearson’s R will be calculated to correlate PROs, functional outcomes, biomechanical outcomes, brain activity, and biomarker outcomes. We use a longitudinal mixed effect model to analyze all outcomes and do not impute missing outcomes. Subjects will be analyzed in the group to which they were randomized regardless of compliance with the assigned intervention. We will evaluate the effect of the number of intervention sessions completed on outcomes. Trial monitoring No regular external trial auditing is scheduled. However, trial monitoring personnel include a safety officer (SO) appointed by the funding body (NIH) and the two PIs, Worthen-Chaudhari (PI) and Lustberg (MPI). Study staff and the PI will review information regarding safety, data quality, and validity on a weekly basis, informing the MPI immediately of any concerns. All data related to recruitment, screening, enrollment, baseline measurement, and intervention measurement will be reviewed weekly by the PI. Data collected from enrolled participants will be reviewed weekly by the statistician with the PI. Additional investigators and study staff will be asked for their input or expertise as needs arise. If unforeseen hazards or risks are identified that may lead to serious adverse events, the PI consults the appropriate members of the team, including the NIH-appointed SO. Adverse event monitoring and reporting Participants randomized to the CON group are asked to report adverse events at the beginning of each week during the SOC period using the MyCap application, a mobile application version of REDCap that participants install on their smart phone devices. Once these participants engage in the intervention (one-way crossover period) they report adverse events on the same schedule as the EXP group. Participants randomized to the EXP arm complete adverse event reporting each time we see them (2x per week) via REDCap. With respect to the adverse event of falls, participants are asked about the incidence of falls and loss of balance. Researchers review REDCap responses once per week for the CON participants within the SOC period and prior to the start of Tango lessons for participants engaging in the Tango intervention (EXP and crossed over CON). If an adverse event is reported, the PI is notified. Classification of the events as Serious or not occurs within 24 hours. Serious adverse events All serious adverse events are immediately reported to the research team and PI and then reported to the IRB, sponsor, and SO within 24 h. Nonserious adverse events Any nonserious adverse events are reported to the SO in biannual meetings and are subject to review prior to receiving authorization for the continuation of the research. Biannual reports A biannual open report summarizing study progress and safety monitoring data is reviewed by the SO and representatives from the NIA/NIA. Approval of the SO is required for the trial to continue. Post-trial care Both Tango and SOC participants continue to report adverse events and CIPN EMA for 6 months post-intervention. Researchers monitor responses and check in with participants as needed. Upon completion of the 6-month follow-up period researchers communicate their appreciation for participation. Protocol amendments Any changes to the protocol require written amendments that must be approved by the NIH and IRB. Upon acceptance from the sponsor and IRB, the PI makes updates to the study record published on ClinicalTrials.gov. If the PI determines that a protocol deviation is necessary for safety reasons, scheduling, recruitment, or personal accommodations for participants, the IRB will be notified immediately. Confidentiality Any physical documentation containing protected health information is stored in a locked cabinet located within research or clinical designated space that is locked and/or monitored when not occupied. Digital documentation is stored in REDCap and/or on secure servers requiring password authentication that are behind secure firewalls. Access to data Study staff, OSU IRB, and representatives of the NIH have access to study data. All those who have access to study data are trained in HIPAA standards for privacy protection and do not refer to confidential information with anyone outside of the study team. Dissemination policy The results of our research will be disseminated to (a) the scientific community; (b) breast cancer survivors; (c) persons with symptoms of neuropathy; (d) participants of the trial who wish to view their data after the 5-year study is complete; and (e) the public. The results of this research will be presented at scientific conferences, including the Multinational Association for Supportive Care in Cancer (MASCC), American Congress of Rehabilitation Medicine (ACRM), and American Society of Biomechanics (ASB). Additionally, results will be published in peer-reviewed journals. Discussion As BC survival rates improve due to available treatments such as chemotherapy, the long-term quality of life for survivors has become a crticial focus of care. The rationale for this study stems from accumulating evidence that PA represents a viable non-pharmacologic avenue to treat one debilitating symptom of survivorship: chronic CIN ( 6 , 17 , 25 ). As a candidate form of neurologic dance training, Tango has been demonstrated to improve quality of life in populations with neuropathology ( 38 , 46 , 54 ). The scientific premise of this study is that Tango stands to achieve more gains than the current medical SOC for CIN by combining PA with rhythmic musical engagement and delivering the intervention in a socially-engaged environment. Based on previous data establishing safety, feasibility, and initial effect of Tango for survivors with CIN ( 38 , 46 ), we have designed a randomized controlled trial to compare the effectiveness of the SOC versus an experimental arm that delivers Tango. We assess comparative effectiveness in terms of patient-reported, functional, and neurophysiologic outcomes relevant to BC survivorship. Our findings may lead to a safe, effective, simple, economical, non-pharmacologic intervention that improves CIN-related deficits and symptoms through activity that can be performed with a friend or loved one. Adding small doses of NDT as standard of care (SOC) for survivors with CIN is a simple, cost-effective solution that can be implemented anywhere in the world without major regulatory hurdles. Better functional recovery for survivors with CIN will lead to improved quality of life, short-term, and long-term health and wellness outcomes for these individuals. Therefore, the risks that participants in this study might incur are minor relative to the potential benefits of improving symptoms and function for BC survivors with CIN and measurable balance deficits. Trial status This study has been active and open for enrollment since January 17th, 2025. Enrollment is expected to be completed by Dec 2028. Intervention delivery and follow-up are expected to be completed by July 1st, 2029. The clinical trial number associated with this trial is NCT06749210. Abbreviations 6mwt 6-minute walk test APP Advanced practice provider BC Breast cancer BDNF Brain-derived neurotropic factor BPI Brief Pain Index BFI Brief Fatigue Index CBC Center for Breast Cancer CCI Co-contraction index CCL-2 Monocyte chemoattractant protein 1 CIN Chemotherapy-induced neuropathy CIPN-20 Chemotherapy-induced peripheral neuropathy 20-item CO-I Co-investigator CON Control group COP Center of pressure COPa Center of pressure area COPv Medial-lateral sway velocity COPM Canadian Occupational Performance Measure CT Connecticut CV Coefficient of variation CXCL-10 Interferon-induced protein 10 EEG Electroencephalography EMA Ecological momentary assessment EMG Electromyography EMR Electronic medical record EXP Experimental group Fz Vertical force GAD-2 Generalized Anxiety Disorder 2-item GFAP Glial fibrillary acidic protein ICAM-1 Endothelial marker – intercellular adhesion molecule 1 IFN-γ Interferon gamma IL-# Interleukin-# IMI Intrinsic motivation inventory IMU Inertial measurement unit IP-10 Interferon-induced protein 10 IRB Institutional Review Board MCP-1 Monocyte chemoattractant protein 1 MDC Macrophage-derived chemokine MIDC Minimum clinically important difference NfL Neurofilament light MPI Multiple principal investigators Mx Moment data about the x-axis My Moment data about the y-axis NT Numbness and Tingling Scale OH Ohio OSU Ohio State University PA Physical activity PHQ-2 Patient Health Questionnaire 2-item PI Principal investigator PRO Patient-reported outcome PRO-CTCAE Patient-Reported Outcome version of the Common Terminology Criteria for Adverse Events QEC Quiet eyes closed QECm Quiet eyes closed with music QOL Quality of life RMSr resultant amplitude of postural control data RMSml medial-lateral amplitude of postural control data RPE-M Rating of perceived exertion – mental RPE-P Rating of perceived exertion - physical SAA Serum amyloid protein SCAT Sports concussion assessment tool SEI Sway complexity SF-36 Short Form Health Survey 36-item SO Safety officer SOC Standard of care SPIRIT Standard Protocol Items: Recommendations for Interventions Trials SSCBC Stefanie Spielman Comprehensive Breast Center Tango Adapted Argentine Tango TGF-α Transforming growth factor-α TNF-α Tumor necrosis factor α TNS Total Neuropathy Score TUG Timed up-and-go TUG-Cog Timed up-and-go cognitive UE Upper extremity VCAM-1 Endothelial marker – vascular cell adhesion molecule 1 WSV Within-subjects variability Declarations Acknowledgements This study is funded by the National Institute of Health, National Institute of Aging, grant R01AG084676-01A1. We acknowledge the National Center for Advancing Translational Sciences, Grant UL1TR00170 as well as participants in this research, the OSU Breast Oncology division, Stephanie Spielman Comprehensive Breast Center, and the Cancer Center Clinical Trials Office, Clinical Trials Processing Laboratory, and Recruitment Intervention and Shared Survey Resource at OSU. Authors’ Contributions LWC and MBL conceived the project, which was developed with input from MEH, PS, GM, and MC. PS developed the statistical analysis plan with input from LWC and MBL. BDL and LWC prepared the manuscript, following a co-author review. All authors reviewed and approved the submission of the final manuscript. All named authors adhere to the authorship guidelines of Trials and have agreed to publication. Funding This study is funded by the National Institute of Health, National Institute of Aging, grant R01AG084676-01A1 and the National Center for Advancing Translational Sciences, Grant UL1TR00170. The decision to submit for publication was made independently by all authors. The funding body is not involved in study design; data collection, analysis, or interpretation; nor writing of this report or the decision to submit this report for publication. Availability of Data and Materials The datasets used and/or established during the current study will be available from the corresponding author upon reasonable request. Ethics Approval and Consent to Participate The study obtained ethics approval by The Ohio State Cancer Institutional Review Board under The Ohio State University’s OHRP Federalwide Assurance #00006378. All participants will provide informed and written consent before taking part. Consent for Publication Not applicable. Competing Interests The authors declare that they have no competing interests. Author Details 1 College of Medicine, Department of Physical Medicine and Rehabilitation, The Ohio State University, Columbus, OH, USA. 3 Department of Nursing, James Cancer Hospital, The Ohio State University, Columbus, OH, USA. 4 Department of Medicine, Division of Geriatrics and Gerontology, Emory University School of Medicine, Atlanta, GA, USA. 5 Atlanta VA Center for Visual and Neurocognitive Rehabilitation, 2015 Uppergate Dr, Atlanta, GA 30307, USA. 6 Division of Occupational Therapy, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. 7 College of Public Health, Division of Biostatistics, The Ohio State University, Columbus, OH, USA. 8 Yale Cancer Center, 333 Cedar St. New Haven, CT 06510, USA. References Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. Cancer Trends Progress Report [Internet]. Bethesda, MD: National Cancer Institute, NIH, DHHS; 2025 Apr [cited 2024 Nov 15]. Available from: https://progressreport.cancer.gov/treatment/breast_cancer Eckhoff L, Knoop As J, Mb, Ewertz M. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer. 2015;51(3):292–300. Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011;125(3):767–74. Lustberg MB, Kuderer NM, Desai A, Bergerot C, Lyman GH. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nat Rev Clin Oncol. 2023;20(8):527–42. Mezzanotte JN, Grimm M, Shinde NV, Nolan T, Worthen-Chaudhari L, Williams NO, et al. Updates in the Treatment of Chemotherapy-Induced Peripheral Neuropathy. Curr Treat Options Oncol. 2022;23(1):29–42. Rodwin RL, Siddiq NZ, Ehrlich BE, Lustberg MB. Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions. Front Pain Res. 2022;3:864910. Song SJ, Min J, Suh SY, Jung SH, Hahn HJ, Im SA, et al. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Support Care Cancer. 2017;25(7):2241–8. Stubblefield MD, Burstien HJ, Burton AW, Custodio CM, Deng GE, Ho M, et al. NCCN task force report: Management of neuropathy in cancer. J Natl Compr Canc Netw. 2009;7(Suppl5):S1–26. Winters-Stone KM, Krasnow SM, Horak FB, Mancini M, Cameron MH, Dieckmann NF, et al. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538). BMC Cancer. 2023;23(1):1087. Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology. 2012;291(1–3):1–9. Li Y, Lustberg MB, Hu S. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers. 2021;13(4):766. Monfort S, Worthen-Chaudhari L, Bigelow K, Chaudhari A. Time-Varying Nature of Postural Control during Eyes Closed Quiet Stance. In: Proceedings of the 42nd Annual Meeting of the American Society of Biomechanics (ASB). Rochester, MN; 2018. Monfort S, Pan X, Patrick R, Singaravelu J, Loprinzi CL, Lustberg MB, et al. Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study. Gait Posture. 2016;48:237–42. Monfort S, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton MJ, et al. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Res Treat. 2017;164(1):69–77. Monfort S, Pan X, Loprinzi CL, Lustberg MB, Chaudhari AMW. Exploring the Roles of Central and Peripheral Nervous System Function in Gait Stability: Preliminary Insights from Cancer Survivors. Gait Posture. 2019;71:62–8. Worthen-Chaudhari LC, Crasta JE, Schnell PM, Lantis K, Martis J, Wilder J et al. Neurologic dance training and home exercise improve motor-cognitive dual-task function similarly, but through potentially different mechanisms, among breast cancer survivors with chemotherapy-induced neuropathy: Initial results of a randomized, controlled clinical trial. J Alzheimer’s Dis. 2024;13872877241291440. Huang MH. Screening and Examination of Fall Risk in Older Cancer Survivors. Rehabil Oncol. 2019;37(2):E7–9. Wechsler S, Wood L. The Effect of Chemotherapy on Balance, Gait, and Falls Among Cancer Survivors: A Scoping Review. Rehabil Oncol. 2021;39(1):6–22. Patel AV, Friedenreich CM, Moore SC, Hayes SC, Silver JK, Campbell KL, et al. American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control. Med Sci Sports Exerc. 2019;51(11):2391–402. Streckmann F, Kneis S, Leifert JA, Baumann FT, Kleber M, Ihorst G, et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann Oncol. 2014;25(2):493–9. Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, et al. Exercise intervention studies in patients with peripheral neuropathy: A systematic review. Sports Med. 2014;44(9):1289–304. Vollmers PL, Mundhenke C, Maass N, Bauerschlag D, Kratzenstein S, Röcken C, et al. Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy. J Cancer Res Clin Oncol. 2018;144(9):1785–92. Wonders KY, Whisler G, Loy H, Holt B, Bohachek K, Wise R. Ten weeks of home-based exercise attenuates symptoms of chemotherapy-induced peripheral neuropathy in breast cancer patients. Health Psychol Res. 2013;1(3):e28. Zimmer P, Trebing S, Timmers-Trebing U, Schenk A, Paust R, Bloch W, et al. Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. Support Care Cancer. 2018;26(2):615–24. Woods JA, Vieira VJ, Keylock KT. Exercise, Inflammation, and Innate Immunity. Immunol Allergy Clin North Am. 2009;29(2):381–93. English AW, Wilhelm JC, Ward PJ. Exercise, Neurotrophins, and Axon Regeneration in the PNS. Physiology. 2014;29(6):437–45. Ludyga S, Gerber M, Pühse U, Looser VN, Kamijo K. Systematic review and meta-analysis investigating moderators of long-term effects of exercise on cognition in healthy individuals. Nat Hum Behav. 2020;4(6):603–12. Worthen-Chaudhari L, Schnell PM, Hackney ME, Lustberg MB. Partnered dance evokes greater intrinsic motivation than home exercise as therapeutic activity for chemotherapy-induced deficits: secondary results of a randomized, controlled clinical trial. Front Psychol. 2024;15:1383143. Hackney ME, Earhart GM. Recommendations for Implementing Tango Classes for Persons with Parkinson Disease. Am J Dance Ther. 2010;32(1):41–52. Dhami P, Moreno S, DeSouza JFX. New framework for rehabilitation-fusion of cognitive and physical rehabilitation: the hope for dancing. Front Psychol [Internet]. 2015 [cited 2024 Nov 20];5. Available from: http://journal.frontiersin.org/article/ 10.3389/fpsyg.2014.01478/abstract Hackney ME, Byers C, Butler G, Sweeney M, Rossbach L, Bozzorg A. Adapted Tango Improves Mobility, Motor–Cognitive Function, and Gait but Not Cognition in Older Adults in Independent Living. J Am Geriatr Soc. 2015;63(10):2105–13. Rehfeld K, Lüders A, Hökelmann A, Lessmann V, Kaufmann J, Brigadski T et al. Dance training is superior to repetitive physical exercise in inducing brain plasticity in the elderly. Buchowski MS, editor. PLOS ONE. 2018;13(7):e0196636. Palo-Bengtsson L, Winblad B, Ekman SL. Social Dancing: a way to support intellectural, emotional and motor functions in persons with dementia. J Psychiatr Ment Health Nurs. 1998;5(6):545–54. Brown S, Martinez MJ, Parsons LM. The Neural Basis of Human Dance. Cereb Cortex. 2005;16(8):1157–67. Federici A, Bellagamba S, Rocchi M. Does dance-based training improve balance in adult and young old subjects? A pilot randomized controlled trial. Aging Clin Exp Res. 2005;17(5):385–9. Ross JM, Warlaumont AS, Abney DH, Rigoli LM, Balasubramaniam R. Influence of musical groove on postural sway. J Exp Psychol Hum Percept Perform. 2016;42(3):308–19. Worthen-Chaudhari L, Lamantia MT, Monfort SM, Mysiw W, Chaudhari AMW, Lustberg MB. Partnered, adapted argentine tango dance for cancer survivors: A feasibility study and pilot study of efficacy. Clin Biomech. 2019;70:257–64. De Dreu MJ, Van Der Wilk ASD, Poppe E, Kwakkel G, Van Wegen EEH. Rehabilitation, exercise therapy and music in patients with Parkinson’s disease: a meta-analysis of the effects of music-based movement therapy on walking ability, balance and quality of life. Parkinsonism Relat Disord. 2012;18:S114–9. Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy. Clin Cancer Res. 2019;25(21):6295–301. Nilsson U. The Anxiety- and Pain‐Reducing Effects of Music Interventions: A Systematic Review. AORN J. 2008;87(4):780–807. Nguyen TN, Nilsson S, Hellström AL, Bengtson A. Music Therapy to Reduce Pain and Anxiety in Children With Cancer Undergoing Lumbar Puncture: A Randomized Clinical Trial. J Pediatr Oncol Nurs. 2010;27(3):146–55. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern Med. 2013;158(3):200. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346(jan08 15):e7586–7586. Hopewell S, Boutron I, Chan AW, Collins GS, De Beyer JA, Hróbjartsson A, et al. An update to SPIRIT and CONSORT reporting guidelines to enhance transparency in randomized trials. Nat Med. 2022;28(9):1740–3. Lantis K, Schnell P, Bland CR, Wilder J, Hock K, Vargo C, et al. Biomechanical effect of neurologic dance training (NDT) for breast cancer survivors with chemotherapy-induced neuropathy: study protocol for a randomized controlled trial and preliminary baseline data. Trials. 2023;24(1):564. Worthen-Chaudhari L, Monfort S, Bland C, Pan X, Chaudhari A. Characterizing within-subject variability in quantified measures of balance control: a cohort study. Gait Posture. 2018;64:141–6. USCS Data Visualizations [Internet]. [cited 2024 Nov 21]. Available from: https://gis.cdc.gov/grasp/USCS/DataViz.html Maki BE, Holliday PJ, Topper AK. A Prospective Study of Postural Balance and Risk of Falling in An Ambulatory and Independent Elderly Population. J Gerontol. 1994;49(2):M72–84. Reed CA, Chaudhari AM, Worthen-Chaudhari LC, Bigelow KE, Monfort SM. A new perspective on transient characteristics of quiet stance postural control. PLoS ONE. 2020;15(8):e0237246. Prieto TE, Myklebust JB, Hoffmann RG, Lovett EG, Myklebust BM. Measures of postural steadiness: differences between healthy young and elderly adults. IEEE Trans Biomed Eng. 1996;43(9):956–66. Roerdink M, Hlavackova P, Vuillerme N. Center-of-pressure regularity as a marker for attentional investment in postural control: A comparison between sitting and standing postures. Hum Mov Sci. 2011;30(2):203–12. Slattery P, Saeri AK, Bragge P. Research co-design in health: a rapid overview of reviews. Health Res Policy Syst. 2020;18(1):17. Hackney ME, McKee K. Community-based adapted tango dancing for individuals with Parkinson’s disease and older adults. J Vis Exp. 2015;94:e52066. McAuley E, Wraith S, Duncan TE. Self-efficacy, perceptions of success, and intrinsic motivation for exercise. J Appl Soc Psychol. 1991;21(2):139–55. Ryan RM, Koestner R, Deci EL. Ego-involved persistence: When free-choice behavior is not intrinsically motivated. Motiv Emot. 1991;15(3):185–205. Ryan RM, Deci EL. Self-Determination Theory and the Facilitation of Intrinsic Motivation, Social Development, and Well-Being. Am Psychol. 2000. Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, et al. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. Oncol Ther. 2021;9(2):385–450. Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer. 2018;26(4):1019–28. Podsiadlo D, Richardson S. The timed Up & Go: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8. Blackwood J, Rybicki K. Assessment of Gait Speed and Timed Up and Go Measures as Predictors of Falls in Older Breast Cancer Survivors. Integr Cancer Ther. 2021;20:15347354211006462. Evans ES, Ketcham CJ, Hibberd JC, Cullen ME, Basiliere JG, Murphy DL. Examination of clinical and laboratory measures of static and dynamic balance in breast cancer survivors. Physiother Theory Pract. 2021;37(11):1199–209. Marshall TF, Zipp GP, Battaglia F, Moss R, Bryan S. Chemotherapy-induced-peripheral neuropathy, gait and fall risk in older adults following cancer treatment. J Cancer Res Pract. 2017;4(4):134–8. Morishita S, Hirabayashi R, Tsubaki A, Aoki O, Fu JB, Onishi H, et al. Assessment of the Mini-Balance Evaluation Systems Test, Timed Up and Go test, and body sway test between cancer survivors and healthy participants. Clin Biomech. 2019;69:28–33. Smith EML, Zanville N, Kanzawa-Lee G, Donohoe C, Bridges C, Loprinzi C, et al. Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data. Support Care Cancer. 2019;27(7):2599–608. Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, et al. Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051. Cleeland CS. Undertreatment of Cancer Pain in Elderly Patients. JAMA. 1998;279(23):1914. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The rapid assessment of fatigue severity in cancer patients: Use of the brief fatigue inventory. Cancer. 1999;85(5):1186–96. Huang MH, Blackwood J, Godoshian M, Pfalzer L. Prevalence of self-reported falls, balance or walking problems in older cancer survivors from Surveillance, Epidemiology and End Results—Medicare Health Outcomes Survey. J Geriatr Oncol. 2017;8(4):255–61. Wild B, Eckl A, Herzog W, Niehoff D, Lechner S, Maatouk I, et al. Assessing Generalized Anxiety Disorder in Elderly People Using the GAD-7 and GAD-2 Scales: Results of a Validation Study. Am J Geriatr Psychiatry. 2014;22(10):1029–38. Li C, Friedman B, Conwell Y, Fiscella K. Validity of the Patient Health Questionnaire 2 (PHQ-2) in identifying major depression in older people. J Am Geriatr Soc. 2007;55(4):596–602. Moskowitz DS, Young SN. Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology. J Psychiatry Neurosci. 2006;31(1):13–20. Tsigilis N, Theodosiou A. Temporal Stability of the Intrinsic Motivation Inventory. Percept Mot Skills. 2003;97(1):271–80. Lamb SE, Jørstad-Stein EC, Hauer K, Becker C, on behalf of the Prevention of Falls Network Europe and Outcomes Consensus Group. Development of a Common Outcome Data Set for Fall Injury Prevention Trials: The Prevention of Falls Network Europe Consensus. J Am Geriatr Soc. 2005;53(9):1618–22. Kneis S, Wehrle A, Dalin D, Wiesmeier IK, Lambeck J, Gollhofer A, et al. A new approach to characterize postural deficits in chemotherapy-induced peripheral neuropathy and to analyze postural adaptions after an exercise intervention. BMC Neurol. 2020;20(1):23. McCrary JM, Goldstein D, Wyld D, Henderson R, Lewis CR, Park SB. Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test. J Cancer Surviv. 2019;13(4):495–502. Bohannon RW, Crouch R. Minimal clinically important difference for change in 6-minute walk test distance results of adults with pathology: A systematic review. J Eval Clin Pract. 2017;23(2):377–81. But-Hadzic J, Dervisevic M, Karpljuk D, Videmsek M, Dervisevic E, Paravlic A, et al. Six-Minute Walk Distance in Breast Cancer Survivors—A Systematic Review with Meta-Analysis. Int J Environ Res Public Health. 2021;18(5):2591. Smith EML. Current Methods for the Assessment and Management of Taxane-Related Neuropathy. Clin J Oncol Nurs. 2013;17(1):22–34. Streckmann F, Elter T, Lehmann HC, Baurecht H, Nazarenus T, Oschwald V, et al. Preventive Effect of Neuromuscular Training on Chemotherapy-Induced Neuropathy: A Randomized Clinical Trial. JAMA Intern Med. 2024;184(9):1046–53. Wołoszyn N, Wiśniowska-Szurlej A, Grzegorczyk J, Kwolek A. The impact of physical exercises with elements of dance movement therapy on the upper limb grip strength and functional performance of elderly wheelchair users living in nursing homes – a randomized control trial. BMC Geriatr. 2021;21(1):423. Bobos P, Nazari G, Lu Z, MacDermid JC. Measurement Properties of the Hand Grip Strength Assessment: A Systematic Review With Meta-analysis. Arch Phys Med Rehabil. 2020;101(3):553–65. Draak TH, Pruppers MH, Van Nes SI, Vanhoutte EK, Bakkers M, Gorson KC, et al. Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar. J Peripher Nerv Syst. 2015;20(3):269–76. Trosclair D, Bellar D, Judge LW, Smith J, Mazerat N, Brignac A. Hand-Grip Strength as a Predictor of Muscular Strength and Endurance. J Strength Cond Res. 2011;25:S99. Law M, Baptiste S, McColl M, Opzoomer A, Polatajko H, Pollock N. The Canadian Occupational Performance Measure: An Outcome Measure for Occupational Therapy. Can J Occup Ther. 1990;57(2):82–7. Carswell A, McColl MA, Baptiste S, Law M, Polatajko H, Pollock N. The Canadian Occupational Performance Measure: A Research and Clinical Literature Review. Can J Occup Ther. 2004;71(4):210–22. McColl MA, Pollock N. Measuring occupational performance using a client-centered perspective. Measuring occupational performance. Routledge; 2024. pp. 83–94. Wressle E, Eeg-Olofsson AM, Marcusson J, Henriksson C. Improved client participation in the rehabilitation process using a client-centred goal formulation structure. J Rehabil Med. 2002;34(1):5–11. Mirelman A, Weiss A, Buchman AS, Bennett DA, Giladi N, Hausdorff JM. Association Between Performance on Timed Up and Go Subtasks and Mild Cognitive Impairment: Further Insights into the Links Between Cognitive and Motor Function. J Am Geriatr Soc. 2014;62(4):673–8. Vervoort D, Vuillerme N, Kosse N, Hortobágyi T, Lamoth CJC. Multivariate Analyses and Classification of Inertial Sensor Data to Identify Aging Effects on the Timed-Up-and-Go Test. Chen K, editor. PLOS ONE. 2016;11(6):e0155984. Hausdorff JM, Rios DA, Edelberg HK. Gait variability and fall risk in community-living older adults: A 1-year prospective study. Arch Phys Med Rehabil. 2001;82(8):1050–6. Maki BE. Gait Changes in Older Adults: Predictors of Falls or Indicators of Fear? J Am Geriatr Soc. 1997;45(3):313–20. Toebes MJP, Hoozemans MJM, Furrer R, Dekker J, Van Dieën JH. Local dynamic stability and variability of gait are associated with fall history in elderly subjects. Gait Posture. 2012;36(3):527–31. Hsieh KL, Trinh L, Sosnoff JJ. Gait variability is altered in cancer survivors with self-reported neuropathy. Gait Posture. 2019;72:206–10. Wright MJ, Twose DM, Gorter JW. Gait characteristics of children and youth with chemotherapy induced peripheral neuropathy following treatment for acute lymphoblastic leukemia. Gait Posture. 2017;58:139–45. Gilchrist L, Tanner L. Gait Patterns in Children With Cancer and Vincristine Neuropathy. Pediatr Phys Ther. 2016;28(1):16–22. Vallabhajosula S, Deaterly CD, Madzima TA. Comparison of forward and backward gait characteristics between those with and without a history of breast cancer. Gait Posture. 2019;74:162–8. Galiano-Castillo N, Arroyo-Morales M, Ariza-Garcia A, Sánchez-Salado C, Fernández-Lao C, Cantarero-Villanueva I, et al. The six-minute walk test as a measure of health in breast cancer patients. J Aging Phys Activ. 2016;24(4):508–15. Dingwell JB, Cusumano JP, Sternad D, Cavanagh PR. Slower speeds in patients with diabetic neuropathy lead to improved local dynamic stability of continuous overground walking. J Biomech. 2000;33(10):1269–77. Dingwell JB, Cavanagh PR. Increased variability of continuous overground walking in neuropathic patients is only indirectly related to sensory loss. Gait Posture. 2001;14(1):1–10. Sloot LH, Van Schooten KS, Bruijn SM, Kingma H, Pijnappels M, Van Dieën JH. Sensitivity of Local Dynamic Stability of Over-Ground Walking to Balance Impairment Due to Galvanic Vestibular Stimulation. Ann Biomed Eng. 2011;39(5):1563–9. Van Schooten KS, Sloot LH, Bruijn SM, Kingma H, Meijer OG, Pijnappels M, et al. Sensitivity of trunk variability and stability measures to balance impairments induced by galvanic vestibular stimulation during gait. Gait Posture. 2011;33(4):656–60. Wiles TM, Kim SK, Stergiou N, Likens AD. Pattern analysis using lower body human walking data to identify the gaitprint. Comput Struct Biotechnol J. 2024;24:281–91. Glover N, WIlder J, Hackney M, Lustberg M, Worthen-Chaudhari L. Case Study in Chemotherapy-Induced Neuropathy: Tango Dance Improved Over-Ground Local Gait Stability. Arch Phys Med Rehabil. 2023;104(3):e16. Chaudhari A, Monfort S, Lamantia M, Lustberg M, Worthen-Chaudhari L. Effect of an Argentine Tango Intervention on Gait Variability in Cancer Survivors: 2413 Board# 4 June 2 9. Med Sci Sports Exerc. 2017;49(5S):675–675. Kneis S, Wehrle A, Freyler K, Lehmann K, Rudolphi B, Hildenbrand B, et al. Balance impairments and neuromuscular changes in breast cancer patients with chemotherapy-induced peripheral neuropathy. Clin Neurophysiol. 2016;127(2):1481–90. Li Q, Wang X, Li X, He X, Wan Q, Yin J, et al. Obtaining High-Quality Blood Specimens for Downstream Applications: A Review of Current Knowledge and Best Practices. Biopreservation Biobanking. 2018;16(6):411–8. Lohmann AE, Dowling RJO, Ennis M, Amir E, Elser C, Brezden-Masley C, et al. Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. JNCI Cancer Spectr. 2018;2(2):pky028. Devasahayam AJ, Kelly LP, Williams JB, Moore CS, Ploughman M. Fitness Shifts the Balance of BDNF and IL-6 from Inflammation to Repair among People with Progressive Multiple Sclerosis. Biomolecules. 2021;11(4):504. Gejl AK, Enevold C, Bugge A, Andersen MS, Nielsen CH, Andersen LB. Associations between serum and plasma brain-derived neurotrophic factor and influence of storage time and centrifugation strategy. Sci Rep. 2019;9(1):9655. Wharton W, Jeong L, Ni L, Bay AA, Shin RJ, McCullough LE, et al. A Pilot randomized clinical trial of adapted tango to improve cognition and psychosocial function in African American women with family history of Alzheimer’s disease (ACT trial). Cereb Circ - Cogn Behav. 2021;2:100018. Benashley L, Bucy A, Wertheim B. Paclitaxel Treatment Effects on Neurofilament Light Chain (NF-L), a Possible Biomarker of Chemotherapy-Induced Peripheral Neuropathy (CIPN). Cancer Epidemiol Biomarkers Prev. 2022;31:1510–1. Burgess BL, Cho E, Honigberg L. Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin. Sci Rep [Internet]. 2022 Sep 16 [cited 2025 May 1];12(1). Available from: https://www.nature.com/articles/s41598-022-18716-5 Kleckner IR, Jusko TA, Culakova E, Chung K, Kleckner AS, Asare M, et al. Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy. Breast Cancer Res Treat. 2021;189(2):521–32. Crasta JE, Thaut MH, Anderson CW, Davies PL, Gavin WJ. Auditory priming improves neural synchronization in auditory-motor entrainment. Neuropsychologia. 2018;117:102–12. Worthen-Chaudhari L, McGonigal J, Logan K, Bockbrader MA, Yeates KO, Mysiw WJ. Reducing concussion symptoms among teenage youth: Evaluation of a mobile health app. Brain Inj. 2017. Supplementary Files DAANCEOSUConsentHIPAASurvivor14.pdf DAANCESPIRITchecklist.docx Cite Share Download PDF Status: Published Journal Publication published 21 Feb, 2026 Read the published version in Trials → Version 1 posted Editorial decision: Major revision 30 Jul, 2025 Reviewers agreed at journal 07 Jul, 2025 Reviewers invited by journal 03 Jul, 2025 Editor assigned by journal 12 Jun, 2025 First submitted to journal 03 Jun, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6814353","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":480133940,"identity":"fd21254a-aa82-4a75-8d4a-99cea977f625","order_by":0,"name":"Bhillie Luciani","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAzElEQVRIiWNgGAWjYBACA4bkBhDJwMbeAOJaEKMlEaqF5wCIK0GsFhCQSACThLWYsye2SfwosMvjk3x+dcOPAgkG/vbuBLxaLHsetkn2GCQXs0nnlN3sATpM4szZDfgddiOxTZrBgBlI5qTd4AFqMZDIJUpLfWKb5Jm0m39I0HIY6CP2Y7eJsgXol2bLHoPjiW08OWy3ZQwkeAj6xZw9+eCNH3+qE+e3H392880fGzn+9l78WpAAjwGYJFY5CLA/IEX1KBgFo2AUjCAAAOXLRV79LKI2AAAAAElFTkSuQmCC","orcid":"https://orcid.org/0009-0003-4278-6195","institution":"The Ohio State University Wexner Medical Center","correspondingAuthor":true,"prefix":"","firstName":"Bhillie","middleName":"","lastName":"Luciani","suffix":""},{"id":480133941,"identity":"7f1ad1d6-a143-4e2f-baa2-f2777bcf1dea","order_by":1,"name":"Martha Carlson","email":"","orcid":"","institution":"The Ohio State University Wexner Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Martha","middleName":"","lastName":"Carlson","suffix":""},{"id":480133942,"identity":"b89f9d54-b283-400e-bec5-60ffe8e05f14","order_by":2,"name":"Gretchen McNally","email":"","orcid":"","institution":"The Ohio State University James Cancer Hospital: The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute","correspondingAuthor":false,"prefix":"","firstName":"Gretchen","middleName":"","lastName":"McNally","suffix":""},{"id":480133943,"identity":"4e8ba51d-be48-4209-a1cd-f6b463ce8a1d","order_by":3,"name":"Madeleine E. Hackney","email":"","orcid":"","institution":"Emory University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Madeleine","middleName":"E.","lastName":"Hackney","suffix":""},{"id":480133944,"identity":"61a9cdfc-13dc-4439-98fc-0fb5a73b9744","order_by":4,"name":"Jewel E. Crasta","email":"","orcid":"","institution":"The Ohio State University Wexner Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Jewel","middleName":"E.","lastName":"Crasta","suffix":""},{"id":480133945,"identity":"ffbedca7-dfee-4e9c-add0-f3c5f2f5eafc","order_by":5,"name":"Patrick Schnell","email":"","orcid":"","institution":"The Ohio State University College of Public Health","correspondingAuthor":false,"prefix":"","firstName":"Patrick","middleName":"","lastName":"Schnell","suffix":""},{"id":480133946,"identity":"2ddbdbd8-cb91-4146-9bda-dce9546fa885","order_by":6,"name":"Maryam B. Lustberg","email":"","orcid":"","institution":"Yale University Yale Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Maryam","middleName":"B.","lastName":"Lustberg","suffix":""},{"id":480133947,"identity":"a96c954b-17bb-4c59-a676-55f255fcbe24","order_by":7,"name":"Lise Worthen-Chaudhari","email":"","orcid":"https://orcid.org/0000-0003-1826-0380","institution":"The Ohio State University Wexner Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Lise","middleName":"","lastName":"Worthen-Chaudhari","suffix":""}],"badges":[],"createdAt":"2025-06-03 20:20:36","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6814353/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6814353/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s13063-026-09486-w","type":"published","date":"2026-02-21T15:59:31+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":86140992,"identity":"f55822e4-5732-4cdb-9cc1-5a94f14f5f4c","added_by":"auto","created_at":"2025-07-07 08:24:13","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":103086,"visible":true,"origin":"","legend":"\u003cp\u003eFlow chart of study design from screening through the follow-up (f/u) period with assessments indicated throughout. Postural control data will be taken at each Tango session in addition to all assessment periods. Each assessment timepoint may contain 1) clinical measures: PROs, dual-task function, and upper extremity function; 2) biomechanical measures: postural control and gait stability; and 3) exploratory measures: biomarker and EEG sampling. For more detailed information, refer to tables 1 \u0026amp; 2. Processing of data will happen after the conclusion of the follow-up period per participant. Analysis of the primary outcome measures will be conducted after all data has been collected.\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-6814353/v1/ec7df4ef97f99bfa83638257.png"},{"id":103251188,"identity":"5029204f-5f22-47de-9177-7699a09d592c","added_by":"auto","created_at":"2026-02-23 16:05:45","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1545232,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6814353/v1/aa890f45-ec20-4f6c-afd6-ca90f879025b.pdf"},{"id":86141054,"identity":"688198e5-d1a4-4af8-bd06-e4bf2486f72f","added_by":"auto","created_at":"2025-07-07 08:24:17","extension":"pdf","order_by":6,"title":"","display":"","copyAsset":false,"role":"supplement","size":183561,"visible":true,"origin":"","legend":"","description":"","filename":"DAANCEOSUConsentHIPAASurvivor14.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6814353/v1/fdc05bfda7f78250c240ba69.pdf"},{"id":86141022,"identity":"184dd9d6-7140-47e5-92db-02f069ca7cd2","added_by":"auto","created_at":"2025-07-07 08:24:15","extension":"docx","order_by":7,"title":"","display":"","copyAsset":false,"role":"supplement","size":40939,"visible":true,"origin":"","legend":"","description":"","filename":"DAANCESPIRITchecklist.docx","url":"https://assets-eu.researchsquare.com/files/rs-6814353/v1/7b491d277458c561b760c856.docx"}],"financialInterests":"","formattedTitle":"Dance-based avenues to advance nonpharmacologic treatment of chemotherapy effects (DAANCE): Study protocol for a multi-center, randomized controlled trial","fulltext":[{"header":"Introduction","content":"\u003ch3\u003eBackground and rationale\u003c/h3\u003e\n\u003cp\u003eBreast cancer (BC) is one of the most diagnosed cancers, with an estimated 2.3\u0026nbsp;million diagnoses in 2020 that disproportionately affected women (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). Of those that receive a BC diagnosis, it is estimated that 64.5% will undergo chemotherapy treatments with taxane-based agents (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e) that cause secondary conditions that complicate aging, such as chemotherapy-induced neuropathy (CIN) (\u003cspan additionalcitationids=\"CR4 CR5 CR6 CR7 CR8\" citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e). Up to 80% of breast cancer survivors who undergo chemotherapy develop CIN (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e). The manifestation of CIN may cause delay or discontinuation of life-saving chemotherapy treatment and decrease quality of life (\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e). Symptoms include disabling pain, numbness, tingling, and/or burning in their hands and feet (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e); a decrease in neuromotor control (\u003cspan additionalcitationids=\"CR14 CR15\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e); deficits in motor-cognitive integration (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e); and increased fall risk (\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e). At present, treatment options for CIN are limited (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e). Despite extensive research, no pharmacologic intervention has significantly improved the neuromotor, functional, and patient-reported symptoms of chronic CIN among BC survivors. Instead, pharmacologic interventions focus on managing symptom development through nerve pain relief (e.g. gabapentin) or serotonin reuptake inhibitors (e.g. duloxetine). However, these pharmacologic solutions come with side effects, such as drowsiness and suicidal ideology. Therefore, there is a critical need to address the neurosensory motor symptoms of neuropathy created through chemotherapy treatments among BC survivors.\u003c/p\u003e \u003cp\u003ePhysical activity (PA) is a promising nonpharmacologic candidate in the treatment of CIN (\u003cspan additionalcitationids=\"CR21 CR22 CR23 CR24\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e). Possible training effects of PA include reduced systemic inflammation (\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e), axonal regeneration in the peripheral nervous system (\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e), and improved executive function (\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e). However, additional research is needed for progressive and prescriptive exercises relevant to the resolution and/or reduction of CIN as well as to understand adherence to a program. Social dance has been proposed as a candidate PA to promote adherence (\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e). Social dance can be delivered as progressively challenging PA (\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e) that addresses functional targets of CIN such as balance and motor-cognitive integration (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan additionalcitationids=\"CR32\" citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e), and promotes intrinsic motivation and adherence over conventional exercise programs (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eAmong potential social dance forms, Adapted Argentine Tango (Tango) has been used to improve motor and cognitive impairments in Parkinson\u0026rsquo;s Disease (\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e), another population that experiences neuropathy and increased fall risk. As a partnered dance, Tango is a form of PA with potential to active the human dynamic system via rhythmic entrainment (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e, \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e), has been associated with better intrinsic motivation to participate than traditional exercise programs (\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e), and may serve as rehabilitation for postural control (\u003cspan additionalcitationids=\"CR37\" citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e), gait function (\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e, \u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e), and patient-reported outcomes of symptoms similar to those reported by BC survivors with CIN (\u003cspan additionalcitationids=\"CR41\" citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e). Further, pilot data show the feasibility of Tango as a potential PA-based solution for cancer survivors with CIN symptoms (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eWe hypothesize that Tango will improve CIN compared to usual care. To evaluate this hypothesis, we will evaluate the effect of Tango, a light to moderate intensity social dance adapted for persons with mobility deficits (\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e, \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e) and breast cancer survivors (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e), on patient-reported symptoms of chronic CIN, function with respect to motor-cognitive integration, and potential physiological mediators of sensation and function among BC survivors. Research by the multiple principal investigators (MPIs) established Tango as feasible for aging survivors (up to 82 years old) to engage in biweekly at a dose of 33(\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e) (mean(SD)) min/session with high satisfaction and positive effects (\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e) and specifically efficacious for motor-cognitive integration in doses of approximately 20 min/class (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e). We hypothesize that Tango will improve sensation, dual-task function, and their potential physiological mediators among BC survivors who demonstrate CIN with balance dysfunction.\u003c/p\u003e\n\u003ch3\u003eObjectives\u003c/h3\u003e\n\u003cp\u003eThe primary objective of this experiment is to rigorously evaluate Tango as a nonpharmacologic intervention for neuropathy symptom relief – including patient-reported numbness and tingling (Aim 1 primary outcome) and dual-task function (Aim 2 primary outcome) - and to establish the first exploratory data regarding mechanisms supporting positive effects, such as change in brain activity, biomechanics, and blood-based biomarkers. We hypothesize that 4 weeks of Tango practice (2x/week; 15–30 min dose of movement-to-music per session) will improve sensation (Aim 1) and dual-task function (Aim 2) more than usual care among BC survivors with CIN and demonstrated balance dysfunction; we further hypothesize that exploratory measures will show change with 8 weeks of Tango practice.\u003c/p\u003e "},{"header":"Methods","content":"\u003cp\u003e\u003cstrong\u003eStudy Design\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis is a multi-center, prospective randomized controlled study of superiority between an experimental intervention and usual care control arm. Eligible participants who provide informed consent will be randomly assigned to the Tango experimental (EXP) or the standard of care (SOC) control group (CON) in a 1:1 ratio. The study primary endpoints are changes from baseline to 4 weeks of intervention in the patient-reported outcome (PRO) of the sensations of numbness and/or tingling (Aim 1) and the quantitative outcome of dual task function during performance of a cognitive challenge simultaneously with a walking task (Aim 2). As an exploratory endpoint, we will assess the effect of Tango on the blood-based biomarkers that potentially mediate sensation and function as well as on cognitive load during a dual-task paradigm as measured by brain activity (i.e. high gamma) (Aim 3). Tables 1 \u0026amp; 2 present the data collection schedule for the EXP and CON groups, formatted per the Standard Protocol Items: Recommendations for Interventions Trials (SPIRIT) recommendations (43\u0026ndash;45). Figure 1 illustrates the overall study design as a flow diagram. As detailed in Tables 1 \u0026amp; 2, outcomes are assessed at the following timepoints: repeated baseline (Baseline), primary endpoint (4 weeks of intervention or SOC), 8 weeks of intervention, 12 weeks (follow-up after a 4-week period of no structured intervention being offered), and weekly for 6 months following intervention end. Secondary outcome measures include clinical and biomechanical tests of function and patient-reported outcomes that complement the primary outcome measures in addition to falls incidence. Tertiary outcome measures, listed in Table 3, include within-session effects, satisfaction collected at session end, and surveys used to inform monitoring and shaping of interventions including Rating of Perceived Exertion - Physical (RPE-P; 6\u0026ndash;20 scale), Rating of Perceived Exertion - Mental (RPE-M; 6-20 scale), and Intrinsic Motivation Inventory (IMI). To support beneficence, individuals randomized to the control arm will be given the option of participating in the experimental intervention after primary outcomes measurement.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eRepeated baseline schedule\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRepeated baseline data have previously been collected and analyzed as described in Lantis et al., 2023 (46). Select measures (Tables 1 \u0026amp; 2, indicated with x\u003csup\u003e\u0026dagger;\u003c/sup\u003e) are collected repeatedly prior to intervention to characterize within-subject variability (WSV) in CIN-related symptoms and function at baseline.\u003c/p\u003e\n\u003cp\u003eSimilar to Lantis et al., 2023 (46), repeated baseline measures for postural control were achieved through collection of the postural control dynamics during silence (QEC) at the beginning of up to 3 visits, including the first screening test of postural control and 3-4 additional days.\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n \u003ctable id=\"Tab3\" border=\"1\"\u003e\n \u003ccaption\u003e\n \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\n \u003cdiv class=\"CaptionContent\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eSPIRIT report of intervention effect outcome measures for EXP group.\u003c/div\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n \u003cth colspan=\"7\" align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eStudy Period\u003c/div\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eEnrollment\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eAllocation\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"4\" align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ePost-Allocation\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eTimepoints\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e3\u0026thinsp;+\u0026thinsp;months post-last taxane exposure\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eBaseline\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e0\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eEXP 4 weeks (Tango midpoint)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eEXP 8 weeks (Tango end)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eEXP 12 weeks (1-month follow up)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e6-month follow up period, assessed weekly\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eENROLLMENT:\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"7\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eEligibility screen\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eInformed consent\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eAllocation\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eASSESSMENTS:\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"7\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eAdverse events (including falls)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eNeuropathy (primary outcome Aim 1)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eTUG-Cog (primary outcome Aim 2)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eCTCAE\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ePain\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eFatigue\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eGAD-2\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ePHQ-2\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eSF-36\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eSatisfaction with intervention\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eActivity outside of study tracking\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eIntrinsic motivation\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ePostural control during silence (QEC)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ePostural control during music listening (QECm)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eTUG\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eTNSr+\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eMiniBEST\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e6mwt (EMG, IMUs)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eUpper extremity function\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eGoal attainment (COPM)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eBlood-based biomarkers\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eCognitive load (EEG)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"8\" align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e\u003csup\u003e\u0026dagger;\u003c/sup\u003e indicates a measure was repeated 3 times\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n \u003ctable id=\"Tab4\" border=\"1\"\u003e\n \u003ccaption\u003e\n \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\n \u003cdiv class=\"CaptionContent\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eSPIRIT report of intervention effect outcome measures for CON group.\u003c/div\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n \u003cth colspan=\"8\" align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eStudy Period\u003c/div\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eEnrollment\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eAllocation\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"5\" align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ePost-Allocation\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eTimepoints\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e3\u0026thinsp;+\u0026thinsp;months post-last taxane exposure\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eBaseline\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e0\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eCON 4 weeks (post-SOC)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eCON 8 weeks (Tango midpoint)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eCON 12 weeks (Tango end)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eCON 16 weeks (1-month follow up)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e6-month follow-up period, assessed weekly\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eENROLLMENT:\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"8\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eEligibility screen\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eInformed consent\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eAllocation\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eASSESSMENTS:\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"8\" align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eAdverse events (including falls)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eNeuropathy (primary outcome Aim 1)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eTUG-Cog (primary outcome Aim 2)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eCTCAE\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ePain\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eFatigue\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eGAD-2\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ePHQ-2\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eSF-36\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eSatisfaction with intervention\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eActivity outside of study tracking\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eIntrinsic motivation\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ePostural control during silence (QEC)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ePostural control during music listening (QECm)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003csup\u003e\u0026dagger;\u003c/sup\u003e\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eTUG\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eTNSr+\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eMiniBEST\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e6mwt (EMG, IMUs)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eUpper extremity function\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eGoal attainment (COPM)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eBlood-based biomarkers\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003eCognitive load (EEG)\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003ex\u003c/div\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"9\" align=\"left\"\u003e\n \u003cdiv class=\"SimplePara\"\u003e\u003csup\u003e\u0026dagger;\u003c/sup\u003e indicates a measure was repeated 3 times\u003c/div\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\n \u003cdiv class=\"gridtable\"\u003e\u0026nbsp;\u0026nbsp;\u003ctable id=\"Tab1\" border=\"1\"\u003e\n \u003ccaption language=\"En\"\u003e\n \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e\n \u003cdiv class=\"CaptionContent\"\u003e\n \u003cp\u003eSPIRIT report of within-session assessments. EMA refers to \u0026ldquo;Ecological Momentary Assessment\u0026rdquo;\u003c/p\u003e\n \u003c/div\u003e\n \u003c/caption\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eSession Type\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eBaseline\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\" colspan=\"2\"\u003e\n \u003cp\u003eTango Intervetion\u003c/p\u003e\n \u003c/th\u003e\n \u003cth align=\"left\"\u003e\n \u003cp\u003eSOC (remote in MyCap app)\u003c/p\u003e\n \u003c/th\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eTimepoints\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eBefore session start (Beg)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eBefore session start (Beg)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAfter completing session (End)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eWeekly\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eASSESSMENTS:\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\" colspan=\"4\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eAdverse events\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNeuropathy retrospective\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePRO-CTCAE retrospective\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePain retrospective (24 hours)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eFatigue retrospective (24 hours)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eNeuropathy EMA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eCTCAE EMA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePain EMA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eFatigue EMA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePostural control during silence (QEC)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ePostural control during music listening (QECm)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eActivity outside of study tracking\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eSatisfaction with session activity as neuropathy treatment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eIntrinsic motivation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003csup\u003ec\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"5\"\u003e\n \u003cp\u003eCOLLECTED TO FACILITATE TRIAL MONITORING AND INTERVENTION SHAPING:\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eRating of perceived physical exertion (RPE-P)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003eRating of perceived mental exertion (RPE-M)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003ctd align=\"left\"\u003e\n \u003cp\u003ex\u003csup\u003eb\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd align=\"left\" colspan=\"5\"\u003e\n \u003cp\u003e\u003csup\u003ea\u003c/sup\u003eRecall period\u0026thinsp;=\u0026thinsp;during the last week, since we last saw you, OR since you last answered these questions (whichever is the shortest time period)\u003c/p\u003e\n \u003cp\u003e\u003csup\u003eb\u003c/sup\u003eRecall period\u0026thinsp;=\u0026thinsp;during the activity just performed\u003c/p\u003e\n \u003cp\u003e\u003csup\u003ec\u003c/sup\u003eQueried every 2 weeks\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n \u003c/table\u003e\n \u003c/div\u003e\n \u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003c/div\u003e\n\n\u003cp\u003e\u003cstrong\u003eStudy setting\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study is currently being conducted at The Ohio State University (OSU) in Columbus, Ohio (OH) and Yale Cancer Center in New Haven, Connecticut (CT). The research protocol has been approved by the OSU Institutional Review Board (IRB) and Yale has ceded review to this board as the single IRB for the multisite clinical trial. At OSU, participants are recruited from the Stephanie Spielman Comprehensive Breast Center (SSCBC) oncology practice as well as from the greater central OH community. At Yale, participants are recruited from the Yale Center for Breast Cancer (CBC) within the Smilow Cancer Center oncology hospital network as well as from the greater south central, CT and northern New York City, New York communities. Consent is obtained in a quiet and private setting prior to research activity either electronically, via REDCap (Research Electronic Data Capture, Nashville, TN), or using a paper version which is stored securely in a locked cabinet within a secure research-dedicated space at the host institutions. Assessments (i.e., screening, repeated baseline, midpoint, post intervention, and 1-month follow-up assessments) are performed in an outpatient care clinic setting or within the volunteer\u0026rsquo;s home environment, as preferred by the survivor. The EXP intervention is performed in a group setting of no more than 15 survivors at a time with their invited partners. The SOC portion of the CON intervention is performed by participants in their own home environment. Participants are compensated $20 per in-person assessment session that does not involve interventional instruction, with an additional $20 compensated for sessions that require sensors to be applied to the skin (potential total of up to $280 for participation in all assessments).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEligibility criteria\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe eligibility criteria of this study follows the criteria described in Lantis et al. (2023) (46). Briefly, participants are eligible for this study if they are 40 years old or older, diagnosed with BC (all stages), experiencing CIN (European Organization for Research and Treatment of Cancer, Chemotherapy-Induced Peripheral Neuropathy outcome measure (CIPN-20) sensorimotor score \u0026gt; 1 or similar on an equivalent measure), finished with taxane-based chemotherapy treatment for at least 3 months, able to understand and comply with directions associated with testing and study treatments, and if they demonstrate postural control measurements outside of normative values (47). Participants are excluded from the study if they meet any of the following criteria: pre-existing vestibular disorders, history of motor deficits or neurological disease other than CIN-related, poorly controlled diabetes (HbA1c \u0026ge; 8.0), non-ambulatory or lower extremity amputation (Note: assistive devices allowed), participating in physical or occupational therapy during the study (Note: engagement in additional therapies or physical activities (e.g. acupuncture) will be documented), or contraindicated to participate in unsupervised activity due to other issues (e.g. herniated vertebral disc).\u003c/p\u003e\n\u003cp\u003eWe expect the study population to be representative of the demographics of the BC survivorship population in the United States between both sites. The CDC reports that 99% of BC cases occur among women and only 1% among men. The CDC census reports the rate of new BC cases in 2019 per 100,000 women by race as White/non-Hispanic 132.5, Black/non-Hispanic 128.4, American Indian and Alaska native/non-Hispanic 101.7, Asian and Pacific Islander/non-Hispanic 104.5, and Hispanic 101.9 (48).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRecruitment and screening\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis research opportunity is posted on public-facing websites including ClinicalTrials.gov (NCT06749210), Research Match, and Study Search to allow volunteers to self-refer by calling a dedicated medical center phone line or emailing the secure address [email protected]. Further, advanced practice providers (APPs) refer eligible and interested clients to our research staff to complete screening. The study staff work onsite within the OSU SSCBC and Yale CBC outpatient facilities at least 2 days per week to follow up with volunteers and referring APPs. In addition, queries are run with electronic medical records (EMR) to identify potentially eligible clients of the OSU academic medical center system. Reports are generated using the criteria of a taxane-based chemotherapy plan being entered in the EMR and filtered by age (\u0026ge; 40 years) and prescribing physician. Through chart review, we identify the subset of clients who meet the study previously mentioned inclusion criteria. Researchers are provided with a list of potential recruits from a pharmacist on staff with SSCBC and Yale Cancer Center, which includes name, stage of breast cancer, whether they were exposed to taxane-based chemotherapy, and medical record number. Clinical research assistants then pre-screen participants from this list using the previously mentioned criteria.\u003c/p\u003e\n\u003cp\u003eFor clients that meet the inclusion criteria, we request approval from the treating oncologist to contact the client for recruitment purposes. Eligible clients who are approved for recruitment by their oncologist are contacted by phone to inquire whether CIN symptoms persist and, if so, to determine interest and availability in participating in this study. Those able and interested are asked to schedule in-person screening of postural control, which involves attempting a short, but challenging balance task reported to distinguish fallers from non-fallers by Maki et al. (1994) (49). As previously reported (50), study volunteers stand quietly and bilaterally for 30 s on a balance plate (Bertec Corp, Columbus, OH) with eyes closed (QEC). Center of pressure (COP) variables of interest are calculated per Prieto et al. (1996) (51) and Roerdink et al. (2011) (52). Survivors are offered enrollment in the study if they demonstrate QEC postural control function that is outside of the estimated 70% confidence interval (CI) (47) of healthy, age-equivalent normative values in (1) COP ellipse area, (2) medial-lateral variability, (3) medial-lateral velocity or outside of the estimated 95% CI in terms of (4) COP complexity. Values corresponding to these inclusion thresholds are \u0026gt;400, \u0026gt;4.0, \u0026gt;11.0, \u0026lt;0.6, respectively.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdequacy of the potential participant pool\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBetween Yale and OSU, approximately 2300 new BC patients are seen annually (Yale n=1000, OSU n=1300), 500+ of whom will receive taxane-based cytotoxic chemotherapy annually. We conservatively estimate that approximately 50% of BC patients treated with cytotoxic chemotherapy will experience persistent CIN and measurable postural control deficits (Worthen-Chaudhari et al., 2018) yielding an eligible patient pool that grows by at least 113 BC survivors per site, per year. In addition to this annual presentation of new individuals with BC, both sites have established survivorship programs that serve thousands of BC survivors, including survivors not seen within our medical centers, who live with chronic CIN. Given the interest in non-pharmacologic options for survivorship treatment and lack of pharmacologic interventions to treat CIN (12), we anticipate screening 500 eligible individuals per year or 40 per month and enrolling up to 25% (i.e., 10 survivors per month) across sites.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eLastly, attending classes with an invited guest (dance partner) was found to affect engagement, by improving attendance of survivors (38). Therefore, we encourage participants to invite a partner to attend training sessions with them and for those who prefer not to invite from their social circle, we provide partners from a pool of talented university students within the relevant departments (e.g. Dance, Music, Health and Rehabilitation Sciences) at both sites to activate social engagement for enrollees randomized to the Tango experimental intervention.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInterventions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe EXP intervention occurs over an 8-week period at a frequency of 2x per week with follow-up measures taken at 12 weeks. The CON intervention starts with 4-weeks of SOC and crosses over to experimental for the following 8 weeks at a frequency of 2x per week. No intervention session with accompanying data collection measures will last longer than 1.25 h total.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eCodesign of Research Study Design and Intervention\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIntegration of patient lived experience and expertise was one of the key objectives for our group (53). \u0026nbsp;Co-design is a meaningful, participatory collaborative process in research design and includes engagement of patient advocates within all stages of the research design and execution process (53). \u0026nbsp;Early on in designing our interventional study, we reached out to our colleague patient advocate for input on the study planning phase. The PIs discussed the intent of the study and reached a shared collaborative understanding of the research question and how to best structure the clinical trial. Decisions at this stage were influential for all subsequent research processes. One of the central changes that occurred as a part of this discussion was shortening the waiting period from 8 weeks to 4 weeks for patients randomized to usual care. The reason for this change was based on careful deliberation of patient advocate input regarding how long survivors living with neuropathy can be expected to wait to receive potential relief through experimental intervention. Our prior work demonstrated relief from CIN dysfunction within 4 weeks of participation in the experimental intervention, therefore, we set the control wait period and primary outcome evaluation for both arms at 4 weeks (17).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eExperimental Intervention: Tango\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe Tango intervention will consist of 16 Adapted Argentine Tango (Adapted Tango) sessions over 8 weeks, adapted for individuals with mobility deficits by co-investigator (Co-I) Hackney (30,54), further adapted for survivors with BC by lead principal investigator (PI) Worthen-Chaudhari (17), and taught by PI Worthen-Chaudhari. We aim to deliver a dose of skilled movement-to-music of at least 10 min and no more than 35 min per session, with breaks for water and rest offered at least every 10 min. Recommendations for implementation of Adapted Tango as a neurologic intervention focus on prevention of falls, use of implicit learning techniques to convey skilled movement goals, the structure of class (warm-up, lesson, cooldown), scaffolding and shaping lessons over time to establish competency in fundamentals, modifications deemed necessary for specific deficits, and music selection (30,54). Each song used within this intervention is from the tango genre with a single song duration of 1.5 to 8.5 min. Participants may sit or rest as needed during or between songs. Instructors ensure appropriate activity wear choices (e.g., footwear, breast support) and ensure qualified volunteers are present to partner with participants. Instructors complete 16 h of training with Co-I Hackney as well as a certification exam to become qualified to teach the Adapted Tango technique. Volunteers who will partner participants for this study complete Co-I Hackney\u0026rsquo;s 4 h Balance Management program plus an additional 3 h of training with PI Worthen-Chaudhari during which live instruction skills are evaluated by the PI before volunteers are cleared to partner participants.\u003c/p\u003e\n\u003cp\u003eThe MPIs previously demonstrated that a Tango dose of about 20 minutes of movement-to-music is feasible for cancer survivors with postural control deficits to participate in at a rate of 2 times per week (17). To optimize factors mediating intrinsic motivation, instruction aims to achieve high Enjoyment and Perceived Competence among participants with low Pressure/Tension (55\u0026ndash;57) as measured by IMI. We administer the IMI every 2 weeks to assess the achievement of these instructional goals. To assure integrity of the training, Co-I Hackney assists MPIs Worthen-Chaudhari and Lustberg to monitor fidelity of the intervention. This subset of our team \u0026ndash; two former professional dancers turned dance scientists and one oncology practitioner \u0026ndash; monitor participant symptoms and training progression and troubleshoot any issues that arise through regular virtual meetings.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eControl intervention with optional 1-way crossover: SOC with EXP\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe active control intervention consists of 4 weeks of SOC, as prescribed by each participant\u0026rsquo;s medical oncologist. Within SOC, medical oncologists may prescribe pharmacologic treatments such as tricyclic antidepressants, anticonvulsants, and serotonin-norepinephrine uptake prohibitors (6,8,58). They may also recommend exercise and/or physical therapy (6). During the 4 weeks, clients are asked, weekly, to document their numbness/tingling due to CIN and any adverse events that occur via a smart phone application (i.e. the MyCap version of REDCap). After completion of outcomes assessments at the primary endpoint of 4 weeks, individuals in the CON arm will have the opportunity to cross over immediately to participate in the EXP tango intervention.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eProcedures/plans to ensure safety of interventions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eProcedures to manage pain, functional guarding, inclement weather, seated interventional options and depression and anxiety monitoring are described in Lantis et al. (2023) (46).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eOutcome measure procedures and analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003ePrimary outcome measures\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eSensation (Aim 1):\u003c/em\u003e\u003c/strong\u003e We measure the impact of Tango on sensation using patient-reported outcomes (PROs) of \u0026ldquo;numbness/tinging/burning\u0026rdquo; via a validated 11-point Likert scale (59) that queries symptom severity in the prior 7 days. All surveys are administered through OSU\u0026rsquo;s instance of the REDCap database for in-person visits and through the REDCap phone application (MyCap) for data entry that participants perform remotely (e.g., SOC activity, follow-up period). Surveys are completed by the participants themselves with no data entry from staff. Answers are reviewed manually by authorized research collaborators, who prompt participants to complete or clarify answers as needed and document their responsibility for review from a list of authorized data reviewers.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eDual-task function (Aim 2):\u003c/em\u003e\u003c/strong\u003e We measure function using validated clinical tests, performed in a clinical space in an area that is distraction free. The \u003cem\u003eTimed Up-and-Go test\u003c/em\u003e \u003cem\u003e(TUG)\u0026nbsp;\u003c/em\u003eis a timed test of a person\u0026rsquo;s ability to stand from a chair, walk 10 feet (3 m), turn around, and return to sitting (60). Presence of CIN has been associated with longer TUG times (61\u0026ndash;64). To measure dual-task function, we use the TUG performed simultaneously with a cognitive task consisting of audibly counting backward by subtracting 3 from a given number \u003cem\u003e(TUG-Cog\u003c/em\u003e). We previously reported that BC survivors with CIN demonstrated dual-task functional deficits with up to 78% demonstrating increased risk of falling as measured by TUG-Cog (17).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eSecondary and tertiary outcome measures\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003ePatient-reported outcome (PRO) survey instruments for measuring symptomatology:\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003ePatient self-report surveys data are collected as described in the \u003cem\u003ePrimary Outcome Measures,\u003c/em\u003e \u003cem\u003eSensation\u003c/em\u003e section above. In addition to the primary PRO-based outcome measure, we collect the following PRO measures:\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eCIN symptoms of temperature.\u0026nbsp;\u003c/em\u003eSelf-reported sensations of \u0026ldquo;hotness\u0026rdquo; or \u0026ldquo;coldness\u0026rdquo; in the last 7 days are collected via a validated 11-point Likert scale (59).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eEuropean Organization\u003c/em\u003e \u003cem\u003efor Research and Treatment of Cancer\u0026rsquo;s Quality of\u003c/em\u003e \u003cem\u003eLife Questionnaire, Chemotherapy-Induced Peripheral\u003c/em\u003e \u003cem\u003eNeuropathy (CIPN-20):\u0026nbsp;\u003c/em\u003eis a validated 20-item patient reported questionnaire instrument for longitudinal evaluation of neuropathy symptoms induced by chemotherapy for a recall period of \u0026ldquo;during the past week\u0026rdquo; (65).\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003cem\u003eOther symptoms.\u0026nbsp;\u003c/em\u003eUsing the Patient-Reported Outcome version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items 39 through 56, cancer-related symptoms such as balance problems, nausea or vomiting, dizziness, sensitivity to light or noise, feeling like \u0026ldquo;in a fog\u0026rdquo;, confusion, sadness, and anxiety can be queried for the recall period of the past 7 days (66).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eThe Brief\u003c/em\u003e \u003cem\u003ePain Inventory (BPI)\u0026nbsp;\u003c/em\u003eis validated to elicit momentary (\u0026ldquo;right now\u0026rdquo;) and retrospective (prior 24 h period) self-reported pain and relevant functional capacity (67).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eThe Brief Fatigue Inventory (BFI)\u0026nbsp;\u003c/em\u003eis validated to elicit momentary (\u0026ldquo;right now\u0026rdquo;) and retrospective (prior 24 h period) self-reported fatigue and relevant functional capacity (68).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eThe Short Form Health Survey (SF-36)\u003c/em\u003e is a quality of life (QOL) measure in cancer survivorship validated to elicit momentary and retrospective (last 4 weeks) assessment of an individuals health status. One report identified this survey as a predictive tool for assessing fall risk amongst cancer survivors (69).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eThe Generalized Anxiety Disorder 2-Item (GAD-2)\u003c/em\u003e is a validated assessment of retrospective (last 2 weeks) self-reported anxiety (70).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eThe Patient Health Questionnaire-2 (PHQ-2)\u003c/em\u003e is a validated assessment of retrospective (last 2 weeks) self-reported depression (Li et al., 2007).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eEcological momentary assessment (EMA).\u0026nbsp;\u003c/em\u003eEMA is a method of experience sampling that captures an individual\u0026rsquo;s self-report of their symptoms \u0026ldquo;right now\u0026rdquo; (72). We modified self-report assessments as needed to elicit self-report of symptoms \u0026ldquo;right now\u0026rdquo; at the beginning and end of intervention sessions as well as remotely through the MyCap phone application. Toward this end we used EMA items from the BPI and BFI and created EMA versions of these surveys: 11-pt Likert scale assessment of numbness and tingling in the extremities, 11-pt Likert scale of hotness and coldness in the extremities and the EORTC CIPN-20. Rather than modifying the PRO-CTCAE items 39 to 56, we used the Sports Concussion Assessment Tool symptom EMA survey of physical, cognitive, and emotional symptoms of mild brain injury which align with PRO-CTCAE items 39 to 56.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eAssessment during the activity just performed:\u0026nbsp;\u003c/em\u003eFinally, to query whether symptomatology was affected by the interventional activity, we modified all PRO instruments to query for the recall period of \u0026ldquo;during the activity just performed\u0026rdquo;.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eSatisfaction with\u003c/em\u003e \u003cem\u003eintervention\u0026nbsp;\u003c/em\u003eis measured after each class using a 7pt Likert scale and prompt for feedback about what did/did not work per class. Feedback is used to improve future sessions\u003cem\u003e.\u003c/em\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eThe Intrinsic Motivation Inventory (IMI)\u0026nbsp;\u003c/em\u003ewas developed from the perspective of Self Determination Theory to assess 7 dimensions of experience: Interest/Enjoyment, Perceived Competence, Effort/Importance, Pressure/Tension, and Choice (73). We administer the 9-item short form of the IMI monthly to optimize instruction around low Pressure/Tension and high Interest/ Enjoyment (56,57) as well as to explore relationships between adherence, motor effects, and IMI dimensions including perceived benefit (i.e., Effort/Importance).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eFunction\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eActivity tracking:\u0026nbsp;\u003c/em\u003eParticipants are asked if they have participated in the following activities: physical therapy, occupational therapy, fitness activity, other therapeutic or fitness activities. If any category of activity is checked as having occurred then participants are prompted to estimate the amount of time spent doing the activity since we last saw them (hours, minutes). If participants indicate that physical or occupational therapy were started during the study period, we remind them that these are an exclusion criterion and give them the choice of postponing engagement in skilled therapy until after completion of the study or termination of study participation.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eFalls tracking:\u0026nbsp;\u003c/em\u003eFalling is defined as an unexpected loss of balance in which an individual comes to rest at a position lower than before the unexpected event (74). We elicit self-report of falls and loss of balance using the question \u0026ldquo;How many times have you fallen or felt like you lost your balance since we last saw you?\u0026rdquo; Responses are typed by the participant and reviewed for incidence of falls, incidence of loss of balance, and details offered about either incidence. During the 6-month follow-up period after intervention end, each participant will use the MyCap application to report falls weekly.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eBarriers to participation:\u0026nbsp;\u003c/em\u003eParticipants are asked \u0026ldquo;To help us understand barriers to participation, if you missed a session, please indicate the reason why you were unable to attend (e.g., schedule conflict, transportation, didn\u0026rsquo;t feel up to it, forgot).\u0026rdquo;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eClinical\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eTo measure \u003cem\u003edynamic balance function\u003c/em\u003e, we collect Mini Balance Evaluation System Test (MiniBEST\u003cem\u003e)\u003c/em\u003e, which evaluates sensory organization, anticipatory and reactive postural control, and dynamic gait indices (75) was found to discriminate BC survivors from controls in at least one prior study (64), and has been recommended for use in studies of neuropathy (18). The subtasks enable calculation of postural control variables of interest for predicting fall risk.\u003c/p\u003e\n\u003cp\u003eTo measure \u003cem\u003ewalking endurance\u003c/em\u003e, we collect the 6-minute walk test (6mwt), which quantifies the distance an individual can walk within 6 minutes, where shorter distances correlate with poorer function including among survivors with CIN (76). Meta-analysis of 6mwt results among adults with pathology or fear of falling indicate that 14.0\u0026ndash;30.5 m represents the minimum clinically-important difference (MCID) for improvement in this measure (77). Among BC survivors, a separate meta-analysis found that BC survivors cover less distance as compared to individuals living without cancer (78). The 6mwt is performed in a designated space within each site\u0026rsquo;s oncology clinic, in a quiet area without distractions. Participants walk in a loop with the following configuration: a straight distance of 19.8 m minimum marked by tape on the floor that participants turn around to their left; participants are cued to walk straight between tape marks and to turn comfortably at the end of each straightaway at the fastest pace they feel they can maintain for 6 min, resting as needed in a standing position before continuing.\u003c/p\u003e\n\u003cp\u003eAs a further measure of CIN and sensation, we will use the \u003cem\u003eTotal Neuropathy Score (TNS) - Revised\u0026nbsp;\u003c/em\u003e(79) (TNSr) \u0026nbsp;with the \u0026ldquo;sense of touch\u0026rdquo; section added per Streckmann et al. (2024) (80). This tool measures peripheral nerve impairments in the upper and lower extremities by evaluating symptoms, sensation, and deep tendon reflexes. In the shortened and revised TNS, subjective sensory symptom presence of tingling, numbness, and pain are evaluated in both the upper and lower extremity. Sensation of vibration is evaluated with a Rydel-Seiffert 128 Hz tuning fork on the bony processes of the upper and lower extremities from distal to proximal, while perception of touch is evaluated by stroking the upper and lower extremities. Finally, deep tendon reflexes of the upper and lower extremities are assessed from distal to proximal.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eUpper extremity (UE) function\u003c/em\u003e will be measured using the back scratch item from the Senior Fitness Test (81). Grip strength will be measured using a standardized digital hand grip dynamometer (Jamar 3-piece Dynamometer, Fabrication Enterprises, Elmsford, NY). In the rehabilitation of individuals with neuropathy, grip strength has shown to be an important clinical outcome in assessing upper extremity impairment and is an important predictor of functional status, muscular endurance, and overall strength (82\u0026ndash;84). Participants will be seated comfortably with their elbow flexed at 90 degrees, forearm in a neutral position, and wrist in slight extension. After a demonstration and one practice attempt, each participant will perform three maximal grip efforts with a rest period of 10 seconds between trials to prevent fatigue. The maximum of the 3 trials will be used for analysis.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eOccupational performance\u003c/em\u003e: The Canadian Occupational Performance Measure (COPM) (85) will be administered through a collaborative process with each participant to identify the patient-reported 5 most important occupations related to self-care, leisure, or productivity. In a semi-structured interview with the study therapist, participants will rate their current performance and satisfaction with performance on each activity using an ordinal scale ranging from 1 to 10 points, with higher scores indicating better scores. These assessments will be conducted at baseline (pre-intervention) and repeated at the conclusion of the intervention (post-intervention) to gauge any changes in functional performance and perceived satisfaction. A change of 2 points is considered the threshold for a clinically meaningful change (85). This individualized, client-centered approach of this COPM instrument allows for precise measurement of intervention outcomes, ensuring that improvements in daily functioning are accurately captured and meaningful to the participants (86\u0026ndash;88).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eBiomechanical\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eMeasures of \u003cem\u003ewalking variability and stability\u003c/em\u003e have been found indicative of mild cognitive impairment (89), age (90), fall risk (91\u0026ndash;93), and neuropathy (94,95) regardless of age or type of cancer (96) including specifically in BC (16,94,97). Gait stability measures will be collected using inertial measurement units (IMUs) (Trigno Centro, Delsys, Natick, MA) affixed to the foot, leg, thigh, pelvis, and/or lower cervical spine during while participants perform the 6mwt (98), where foot IMU sensors will detect heel strike and toe off events within the gait cycle. The non-linear measures of local dynamic stability (99\u0026ndash;102) and recurrent quantification analysis (RQA) (103) will also be analyzed. An IMU sensor placed on the upper torso (C7 vertebral spine) will collect gyroscopic data to detect bouts of steady-state walking behavior along a straight path within the 6mwt. Steady-state bouts of walking that are longer than 4 strides (101,104) will be used to calculate non-linear measures of gait stability. From this, mean Lyapanov exponent and RQA measures will be calculated over the course of the 6mwt. From the steady-state bouts, the coefficient of variation (CV) will also be calculated for step length, gait speed, and other measures of variability previously found sensitive to health status (91,92,105).\u003c/p\u003e\n\u003cp\u003eWe measure \u003cem\u003epostural control\u003c/em\u003e through center of pressure (COP) data collected in accordance with our group\u0026rsquo;s previous studies of balance deficits (46,47,50). Data are recorded on a portable balance plate (Bertec Corporation, Columbus, OH) at while participants stand on the plate quietly with their eyes closed (QEC). The data are captured using custom software written in LabVIEW (National Instruments, Austin, TX) at a sampling frequency of 1000 Hz and consist of one channel of vertical force data (Fz) and two channels of moment data (Mx, My) over time.\u003c/p\u003e\n\u003cp\u003eAdditionally, we complete the QEC measure while listening to music (QECm) to examine the relationship between music listening and postural control over the course of the intervention, as it has been shown that postural control improved amongst healthy college-aged individuals after listening to music (37). We follow the same protocol listed in our group\u0026rsquo;s previous work, where a participant completes a QEC posture while listening to the musical composition \u0026quot;La Cumparsita\u0026quot; (46).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFrom the QEC and QECm data, we calculate the COP time series for the 30-s duration of QEC condition performance. We then calculate the measures of future fall risk from the two tasks: COP variability in resultant and medial\u0026ndash; lateral planes (RMSr, RMSml), medial-lateral sway velocity (COPv), and 95% ellipse area (COPa) for the 30-s duration per Prieto et al., (1996) (51) well as sample entropy using the increment method of calculation (SEI) (52).\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eCo-contraction index (CCI)\u003c/em\u003e is the ratio of the muscle activity produced in the agonist versus the antagonist muscles of the leg, measured via electromyography (EMG), which can provide unique insights into neuropathy effects (106). For this protocol, we measure signals in the tibialis anterior, lateral gastrocnemius, and soleus muscles during performance of the 6mwt, QEC, and QECm tasks.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eExploratory measures\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eBlood-based biomarkers\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBlood sample data collections will occur at baseline, after 4 weeks of usual care for members of the CON group, and after 8 weeks of intervention for members of the EXP group. Blood sample collections will occur in the same facilities mentioned in the \u003cem\u003eStudy Setting\u003c/em\u003e section, during scheduled clinical or research appointments. Blood will be drawn in two 6 mL EDTA tubes at the timepoints described previously. Best practice regarding collection and centrifugation will be followed to extract the plasma layer and store aliquots (107). All cryovials containing plasma will be labeled and stored in a -80\u0026deg;C freezer, accessible to laboratory personnel only. Aliquots from each timepoint per participant ID will be shipped to Yale facilities for further processing on an annual basis.\u003c/p\u003e\n\u003cp\u003eBlood-based biomarkers of interest include targeted indices linked to breast cancer (7,108), neurorecovery (109\u0026ndash;111), and neurotoxicity/trauma (7,112). Panels of markers will be measured in plasma. We will investigate a battery of biomarkers using singleplex assays. We list these in order of priority for analysis below in the even that unexpected funding changes impact biomarker analysis budget:\u003c/p\u003e\n\u003col\u003e\n \u003cli\u003eNeurofilament light (NfL) and glial fibrillary acidic protein (GFAP) (Benashley et al., 2022; Burgess et al., 2022; Rodwin et al., 2022).\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eInterleukin-6 (IL-6), IL-10, brain-derived neurotropic factor (BDNF) (7,114), tumor necrosis factor \u0026alpha; (TNF-\u0026alpha;) (109,111).\u003c/li\u003e\n \u003cli\u003eOther cytokine and inflammatory biomarkers associated with neurotoxicity including but not limited to:\u0026nbsp;IL-7, IL-8, IL-9, interferon gamma (IFN-\u0026gamma;), interferon induced protein 10 (IP-10; CXCL-10), macrophage derived chemokine (MDC), monocyte chemoattractant protein 1 (MCP1; CCL-2), transforming growth factor-\u0026alpha; (TGF-\u0026alpha;), serum amyloid protein (SAA), endothelial markers (ICAM-1, VCAM-1) (108,109).\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAt the baseline, after 4 weeks for the CON group, and after 8 weeks for the EXP group, we will measure NfL, a neuronal cytoskeletal protein that has indicated axonal damage in animal CIN models and survivors (7). NfL serum concentration will be assessed by ultrasensitive single molecule array (Simoa NF-Light\u0026reg; assay, Quanterix, Billerica, MA).\u003c/p\u003e\n\u003cp\u003eWe will investigate synaptic plasticity through via BDNF and GFAP, sampled at baseline, after 4 weeks for the CON group, and after 8 weeks for the EXP group. BDNF levels will be analyzed at the Yale facility, while GFAP levels will be assessed by the Quanterix laboratory (Quanterix, Billerica, MA).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eCognitive load\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBrain activity will be collected via electroencephalography (EEG) and occur at baseline, after 4 weeks of SOC or INT, and after 8 weeks of intervention. EEG data collection will occur in the same facilities mentioned in the \u003cem\u003eStudy Setting\u003c/em\u003e section, using a mobile EEG system (eego, ANT Neuro, Netherlands) with 24-channels (waveguard net, ANT Neuro, Netherlands), sampling at a frequency of 2048 Hz. EEG signal processing and analysis will follow Crasta et al. (2018) (115) using BV Analyzer (Brain Vision LLC, Garner, NC) to extract mean activity per frequency band, phase synchrony, and event-related potentials.\u003c/p\u003e\n\u003cp\u003eThe protocol to assess cognitive load follows that of Worthen-Chaudhari et el., 2024 (17). EEG signals were collected during the performance of the following postural and motor-cognitive tasks. Conditions listed in Table 4 below are completed by each participant while standing with their shoes off, feet 7 cm apart from the inside of their feet, hands to their side, and facing comfortably straight ahead. Participants will be guarded by trained research staff during standing tasks and will get a break at the halfway mark of each task. Each task lasts for 3 minutes. Auditory stimuli will be presented through ER-3A-inserted earphones (Etymotic Research, Elk Grove Village, IL) via a custom-made program in PsychoPy (Open Science Tools, Nottingham, England).\u0026nbsp;\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eTable 4:\u0026nbsp;\u003c/strong\u003eEEG conditions\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 240px;\"\u003e\n \u003cp\u003eCondition\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 384px;\"\u003e\n \u003cp\u003eDescription\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 240px;\"\u003e\n \u003cp\u003eSeated, eyes open\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 384px;\"\u003e\n \u003cp\u003eResting data collected while seated. Participants will be instructed to watch a fixation point on a screen in front of them.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 240px;\"\u003e\n \u003cp\u003eQuiet standing, eyes open\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 384px;\"\u003e\n \u003cp\u003eParticipants will be instructed to stand with their eyes open while viewing a fixation point on a screen in front of them.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 240px;\"\u003e\n \u003cp\u003eQuiet standing, eyes closed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 384px;\"\u003e\n \u003cp\u003eParticipants will be instructed to stand with their eyes closed.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 240px;\"\u003e\n \u003cp\u003eStanding, eyes open with music\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 384px;\"\u003e\n \u003cp\u003eParticipants will be instructed to stand while Tango music is played. They will be instructed to watch a fixation point on a screen in front of them.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 240px;\"\u003e\n \u003cp\u003eStanding, eyes closed with music\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 384px;\"\u003e\n \u003cp\u003eParticipants will be instructed to stand with their eyes closed while Tango music is played.\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 240px;\"\u003e\n \u003cp\u003eVisual oddball\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 384px;\"\u003e\n \u003cp\u003eWhile standing, participants will be instructed to mentally count how many odd stimuli (yellow square in the center of the screen) are present while ignoring the repetitive stimuli (red square in the center of the screen).\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 240px;\"\u003e\n \u003cp\u003eAuditory oddball\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 384px;\"\u003e\n \u003cp\u003eWhile standing, participants will be instructed to mentally count the oddball tone (1500 Hz) and ignore the standard tone (1000 Hz).\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFor the visual and auditory oddball, each stimulus is presented for 500 ms with a random inter-stimulus interval from 500 ms to 1 second. A total of 100 stimuli are presented (80 standard and 20 oddball).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eWithin-session effect\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAt the beginning and end of each in-person intervention session, we collect a subset of PRO data with which to evaluate the effect of the session (Table 3). Each PRO measurement is collected from participants using a computer, a touch screen tablet, or a cell phone.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePower calculations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAllowing for up to approximately 30% loss to follow-up, we plan to enroll 70 subjects per arm to retain 50 per arm per site. This drop-out rate is conservative, corresponding to criteria that we used previously to assess an intervention\u0026rsquo;s feasibility (38,116). We use a two-sample t-test 5% significance level (two-sided) as a conservative approximation to our analysis procedure. Due to additional covariate information and early information from subjects lost to follow-up, we expect greater power from our linear mixed model analysis.\u003c/p\u003e\n\u003cp\u003eTo calculate effect size of the Aim 1 primary outcome measure: CIN sensation, we used the Numbness and Tingling (NT) 11-point scale (i.e., 0\u0026ndash;10) from a study of physical activity for CIN among MBC survivors that observed post-chemotherapy scores with a standard deviation of 2.5 in the control arm and 1.9 in the treatment arm\u0026nbsp;(Kleckner et al., 2018). Using the same standard deviations we have approximately 80% power to detect a minimum clinically significant difference of 1.25 (corresponding to minimally clinically important difference of 2.5 points on the 0\u0026ndash;20 CIN-20 5-item sensory scale).\u003c/p\u003e\n\u003cp\u003eTo calculate effect size of the Aim 2 primary outcome measure: dual-task function in the motor and cognitive domains, we used an effect size of 0.56 (Cohen\u0026rsquo;s \u003cem\u003ed\u003c/em\u003e) based on preliminary data from 14 BC survivors with CIN participating in our pilot work (R21-AG068831); the effect size was verified as a conservative estimate as compared to a later calculation using a larger cohort of 46 BC survivors with CIN (17). Enrolling 70 participants per group (140 total) allows for a drop-out rate of up to 30% to yield full follow-up on 50 participants per arm and 80% power to detect the target effect size at the 5% significance level. This drop-out rate is conservative, corresponding to the criteria that we previously used to assess an intervention\u0026rsquo;s feasibility (38,116).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRandomization\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAfter a participant has qualified, consented to participate in this trial, and completed repeated baseline testing, researchers randomize them 1:1 into one of two groups: EXP or CON. Randomization is blocked and stratified by site, age (\u0026ge;61 vs \u0026lt;61), baseline CIN sensation (Likert \u0026ge;4 vs \u0026lt;4), and baseline functional status (TUG-Cog \u0026ge;12.64 s vs \u0026lt;12.64 s) based on the results of previous work in our lab (17). CIN sensation was identified through the 11-point Likert scale (59) administered during the repeated baseline period. Functional status is identified by averaging the times of 3 TUG-Cog trials that participants completed during the repeated baseline period.\u003c/p\u003e\n\u003cp\u003eRandomization is accomplished using a schedule that was generated by the statistician prior to the trial opening to enrollment. The clinical research coordinator will assign allocation and enroll participants. One member of the research team is blinded to the randomization schedule prior to allocation; this researcher administers TUG and TUG-Cog to participants throughout the study. Study participants cannot be blinded; they will inevitably know their group assignment as they are participating in a distinct intervention in comparison to usual care.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData management\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eEach study participant is assigned a unique six-digit identification number that cannot be traced to their protected health information. Participant data, coded using these identification numbers, are stored in a central database using REDCap. REDCap is a secure web-based platform that is designed for clinical trials which meets both HIPAA and 21 CFR. Clinical and biomechanical data are collected by study staff who input results into REDCap manually or via data upload. PRO data is manually entered into REDCap by study participants: participants undergoing the Tango intervention fill out questionnaires within REDCap before the start and at the end of each Tango session. SOC participants fill out questionnaires within MyCap, a mobile device application of REDCap once per week during the SOC wit period, for the purpose of adverse events reporting and symptoms tracking, then transition into the Tango intervention protocol in which they fill out questionnaires within REDCap before the start and end of each Tango session.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll outcome analyses will be performed on an intent-to-treat basis, and all hypothesis tests will be two-sided and at the 5% significance level or 95% confidence level. Longitudinal linear mixed models will be used to model changes in PROs and dual-task function. Fixed effects will be included for condition, session number within condition, baseline outcome measure, age, diabetes status, physical fitness activity (defined by weekly duration and metabolic equivalents), and number of previous chemotherapy lines. Random effects for subjects and study center will be used to account for within-subject and within-center correlation, and covariance estimated by restricted maximum likelihood. Exploratory Aim 3 will be assessed via causal mediation analysis using marginal structural models. The primary estimand will be the contrast representing the difference in mean change in outcome measure from baseline to week 4 (end of randomized treatment comparison) between treatment groups.\u003c/p\u003e\n\u003cp\u003eWhile we expect balance between groups due to randomization, we will adjust for potential confounders including age, body mass index, concurrent medications, and other variables if an imbalance between groups occurs by chance. Pearson\u0026rsquo;s \u003cem\u003eR\u0026nbsp;\u003c/em\u003ewill be calculated to correlate PROs, functional outcomes, biomechanical outcomes, brain activity, and biomarker outcomes. We use a longitudinal mixed effect model to analyze all outcomes and do not impute missing outcomes. Subjects will be analyzed in the group to which they were randomized regardless of compliance with the assigned intervention. We will evaluate the effect of the number of intervention sessions completed on outcomes.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTrial monitoring\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNo regular external trial auditing is scheduled. However, trial monitoring personnel include a safety officer (SO) appointed by the funding body (NIH) and the two PIs, Worthen-Chaudhari (PI) and Lustberg (MPI). Study staff and the PI will review information regarding safety, data quality, and validity on a weekly basis, informing the MPI immediately of any concerns. All data related to recruitment, screening, enrollment, baseline measurement, and intervention measurement will be reviewed weekly by the PI. Data collected from enrolled participants will be reviewed weekly by the statistician with the PI. Additional investigators and study staff will be asked for their input or expertise as needs arise. If unforeseen hazards or risks are identified that may lead to serious adverse events, the PI consults the appropriate members of the team, including the NIH-appointed SO.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdverse event monitoring and reporting\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eParticipants randomized to the CON group are asked to report adverse events at the beginning of each week during the SOC period using the MyCap application, a mobile application version of REDCap that participants install on their smart phone devices. Once these participants engage in the intervention (one-way crossover period) they report adverse events on the same schedule as the EXP group. Participants randomized to the EXP arm complete adverse event reporting each time we see them (2x per week) via REDCap. With respect to the adverse event of falls, participants are asked about the incidence of falls and loss of balance. Researchers review REDCap responses once per week for the CON participants within the SOC period and prior to the start of Tango lessons for participants engaging in the Tango intervention (EXP and crossed over CON). If an adverse event is reported, the PI is notified. Classification of the events as Serious or not occurs within 24 hours.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eSerious adverse events\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll serious adverse events are immediately reported to the research team and PI and then reported to the IRB, sponsor, and SO within 24 h.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eNonserious adverse events\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAny nonserious adverse events are reported to the SO in biannual meetings and are subject to review prior to receiving authorization for the continuation of the research.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eBiannual reports\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA biannual open report summarizing study progress and safety monitoring data is reviewed by the SO and representatives from the NIA/NIA. Approval of the SO is required for the trial to continue.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003ePost-trial care\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBoth Tango and SOC participants continue to report adverse events and CIPN EMA for 6 months post-intervention. Researchers monitor responses and check in with participants as needed. Upon completion of the 6-month follow-up period researchers communicate their appreciation for participation.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eProtocol amendments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAny changes to the protocol require written amendments that must be approved by the NIH and IRB. Upon acceptance from the sponsor and IRB, the PI makes updates to the study record published on ClinicalTrials.gov. If the PI determines that a protocol deviation is necessary for safety reasons, scheduling, recruitment, or personal accommodations for participants, the IRB will be notified immediately.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConfidentiality\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAny physical documentation containing protected health information is stored in a locked cabinet located within research or clinical designated space that is locked and/or monitored when not occupied. Digital documentation is stored in REDCap and/or on secure servers requiring password authentication that are behind secure firewalls.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAccess to data\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eStudy staff, OSU IRB, and representatives of the NIH have access to study data. All those who have access to study data are trained in HIPAA standards for privacy protection and do not refer to confidential information with anyone outside of the study team.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDissemination policy\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe results of our research will be disseminated to (a) the scientific community; (b) breast cancer survivors; (c) persons with symptoms of neuropathy; (d) participants of the trial who wish to view their data after the 5-year study is complete; and (e) the public. The results of this research will be presented at scientific conferences, including the Multinational Association for Supportive Care in Cancer (MASCC), American Congress of Rehabilitation Medicine (ACRM), and American Society of Biomechanics (ASB). Additionally, results will be published in peer-reviewed journals.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eAs BC survival rates improve due to available treatments such as chemotherapy, the long-term quality of life for survivors has become a crticial focus of care. The rationale for this study stems from accumulating evidence that PA represents a viable non-pharmacologic avenue to treat one debilitating symptom of survivorship: chronic CIN (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e). As a candidate form of neurologic dance training, Tango has been demonstrated to improve quality of life in populations with neuropathology (\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e, \u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e, \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e). The scientific premise of this study is that Tango stands to achieve more gains than the current medical SOC for CIN by combining PA with rhythmic musical engagement and delivering the intervention in a socially-engaged environment. Based on previous data establishing safety, feasibility, and initial effect of Tango for survivors with CIN (\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e, \u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e), we have designed a randomized controlled trial to compare the effectiveness of the SOC versus an experimental arm that delivers Tango. We assess comparative effectiveness in terms of patient-reported, functional, and neurophysiologic outcomes relevant to BC survivorship. Our findings may lead to a safe, effective, simple, economical, non-pharmacologic intervention that improves CIN-related deficits and symptoms through activity that can be performed with a friend or loved one. Adding small doses of NDT as standard of care (SOC) for survivors with CIN is a simple, cost-effective solution that can be implemented anywhere in the world without major regulatory hurdles. Better functional recovery for survivors with CIN will lead to improved quality of life, short-term, and long-term health and wellness outcomes for these individuals. Therefore, the risks that participants in this study might incur are minor relative to the potential benefits of improving symptoms and function for BC survivors with CIN and measurable balance deficits.\u003c/p\u003e\n\u003ch3\u003eTrial status\u003c/h3\u003e\n\u003cp\u003eThis study has been active and open for enrollment since January 17th, 2025. Enrollment is expected to be completed by Dec 2028. Intervention delivery and follow-up are expected to be completed by July 1st, 2029. The clinical trial number associated with this trial is NCT06749210.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003e6mwt 6-minute walk test\u003c/p\u003e\n\u003cp\u003eAPP Advanced practice provider\u003c/p\u003e\n\u003cp\u003eBC Breast cancer\u003c/p\u003e\n\u003cp\u003eBDNF Brain-derived neurotropic factor\u003c/p\u003e\n\u003cp\u003eBPI Brief Pain Index\u003c/p\u003e\n\u003cp\u003eBFI Brief Fatigue Index\u003c/p\u003e\n\u003cp\u003eCBC Center for Breast Cancer\u003c/p\u003e\n\u003cp\u003eCCI Co-contraction index\u003c/p\u003e\n\u003cp\u003eCCL-2 Monocyte chemoattractant protein 1\u003c/p\u003e\n\u003cp\u003eCIN Chemotherapy-induced neuropathy\u003c/p\u003e\n\u003cp\u003eCIPN-20 Chemotherapy-induced peripheral neuropathy 20-item\u003c/p\u003e\n\u003cp\u003eCO-I Co-investigator\u003c/p\u003e\n\u003cp\u003eCON Control group\u003c/p\u003e\n\u003cp\u003eCOP Center of pressure\u003c/p\u003e\n\u003cp\u003eCOPa Center of pressure area\u003c/p\u003e\n\u003cp\u003eCOPv Medial-lateral sway velocity\u003c/p\u003e\n\u003cp\u003eCOPM Canadian Occupational Performance Measure\u003c/p\u003e\n\u003cp\u003eCT Connecticut\u003c/p\u003e\n\u003cp\u003eCV Coefficient of variation\u003c/p\u003e\n\u003cp\u003eCXCL-10 Interferon-induced protein 10\u003c/p\u003e\n\u003cp\u003eEEG Electroencephalography\u003c/p\u003e\n\u003cp\u003eEMA Ecological momentary assessment\u003c/p\u003e\n\u003cp\u003eEMG Electromyography\u003c/p\u003e\n\u003cp\u003eEMR Electronic medical record\u003c/p\u003e\n\u003cp\u003eEXP Experimental group\u003c/p\u003e\n\u003cp\u003eFz Vertical force\u003c/p\u003e\n\u003cp\u003eGAD-2 Generalized Anxiety Disorder 2-item\u003c/p\u003e\n\u003cp\u003eGFAP Glial fibrillary acidic protein\u003c/p\u003e\n\u003cp\u003eICAM-1 Endothelial marker – intercellular adhesion molecule 1\u003c/p\u003e\n\u003cp\u003eIFN-γ Interferon gamma\u003c/p\u003e\n\u003cp\u003eIL-# Interleukin-#\u003c/p\u003e\n\u003cp\u003eIMI Intrinsic motivation inventory\u003c/p\u003e\n\u003cp\u003eIMU Inertial measurement unit\u003c/p\u003e\n\u003cp\u003eIP-10 Interferon-induced protein 10\u003c/p\u003e\n\u003cp\u003eIRB Institutional Review Board\u003c/p\u003e\n\u003cp\u003eMCP-1 Monocyte chemoattractant protein 1\u003c/p\u003e\n\u003cp\u003eMDC Macrophage-derived chemokine\u003c/p\u003e\n\u003cp\u003eMIDC Minimum clinically important difference\u003c/p\u003e\n\u003cp\u003eNfL Neurofilament light\u003c/p\u003e\n\u003cp\u003eMPI Multiple principal investigators\u003c/p\u003e\n\u003cp\u003eMx Moment data about the x-axis\u003c/p\u003e\n\u003cp\u003eMy Moment data about the y-axis\u003c/p\u003e\n\u003cp\u003eNT Numbness and Tingling Scale\u003c/p\u003e\n\u003cp\u003eOH Ohio\u003c/p\u003e\n\u003cp\u003eOSU Ohio State University\u003c/p\u003e\n\u003cp\u003ePA Physical activity\u003c/p\u003e\n\u003cp\u003ePHQ-2 Patient Health Questionnaire 2-item\u003c/p\u003e\n\u003cp\u003ePI Principal investigator\u003c/p\u003e\n\u003cp\u003ePRO Patient-reported outcome\u003c/p\u003e\n\u003cp\u003ePRO-CTCAE Patient-Reported Outcome version of the Common Terminology Criteria for Adverse Events\u003c/p\u003e\n\u003cp\u003eQEC Quiet eyes closed\u003c/p\u003e\n\u003cp\u003eQECm Quiet eyes closed with music\u003c/p\u003e\n\u003cp\u003eQOL Quality of life\u003c/p\u003e\n\u003cp\u003eRMSr resultant amplitude of postural control data\u003c/p\u003e\n\u003cp\u003eRMSml medial-lateral amplitude of postural control data\u003c/p\u003e\n\u003cp\u003eRPE-M Rating of perceived exertion – mental\u003c/p\u003e\n\u003cp\u003eRPE-P Rating of perceived exertion - physical\u003c/p\u003e\n\u003cp\u003eSAA Serum amyloid protein\u003c/p\u003e\n\u003cp\u003eSCAT Sports concussion assessment tool\u003c/p\u003e\n\u003cp\u003eSEI Sway complexity\u003c/p\u003e\n\u003cp\u003eSF-36 Short Form Health Survey 36-item\u003c/p\u003e\n\u003cp\u003eSO Safety officer\u003c/p\u003e\n\u003cp\u003eSOC Standard of care\u003c/p\u003e\n\u003cp\u003eSPIRIT Standard Protocol Items: Recommendations for Interventions Trials\u003c/p\u003e\n\u003cp\u003eSSCBC Stefanie Spielman Comprehensive Breast Center\u003c/p\u003e\n\u003cp\u003eTango Adapted Argentine Tango\u003c/p\u003e\n\u003cp\u003eTGF-α Transforming growth factor-α\u003c/p\u003e\n\u003cp\u003eTNF-α Tumor necrosis factor α\u003c/p\u003e\n\u003cp\u003eTNS Total Neuropathy Score\u003c/p\u003e\n\u003cp\u003eTUG Timed up-and-go\u003c/p\u003e\n\u003cp\u003eTUG-Cog Timed up-and-go cognitive\u003c/p\u003e\n\u003cp\u003eUE Upper extremity\u003c/p\u003e\n\u003cp\u003eVCAM-1 Endothelial marker – vascular cell adhesion molecule 1\u003c/p\u003e\n\u003cp\u003eWSV Within-subjects variability\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study is funded by the National Institute of Health, National Institute of Aging, grant R01AG084676-01A1. We acknowledge the National Center for Advancing Translational Sciences, Grant UL1TR00170 as well as participants in this research, the OSU Breast Oncology division, Stephanie Spielman Comprehensive Breast Center, and the Cancer Center Clinical Trials Office, Clinical Trials Processing Laboratory, and Recruitment Intervention and Shared Survey Resource at OSU.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; Contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eLWC and MBL conceived the project, which was developed with input from MEH, PS, GM, and MC. PS developed the statistical analysis plan with input from LWC and MBL. BDL and LWC prepared the manuscript, following a co-author review. All authors reviewed and approved the submission of the final manuscript. All named authors adhere to the authorship guidelines of Trials and have agreed to publication.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study is funded by the National Institute of Health, National Institute of Aging, grant R01AG084676-01A1 and the National Center for Advancing Translational Sciences, Grant UL1TR00170. The decision to submit for publication was made independently by all authors. The funding body is not involved in study design; data collection, analysis, or interpretation; nor writing of this report or the decision to submit this report for publication.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of Data and Materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets used and/or established during the current study will be available from the corresponding author upon reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eEthics Approval and Consent to Participate\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study obtained ethics approval by The Ohio State Cancer Institutional Review Board under The Ohio State University\u0026rsquo;s OHRP Federalwide Assurance #00006378. All participants will provide informed and written consent before taking part.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eConsent for Publication\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eCompeting Interests\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor Details\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e1\u003c/sup\u003eCollege of Medicine, Department of Physical Medicine and Rehabilitation, The Ohio State University, Columbus, OH, USA. \u003csup\u003e3\u003c/sup\u003eDepartment of Nursing, James Cancer Hospital, The Ohio State University, Columbus, OH, USA. \u003csup\u003e4\u003c/sup\u003eDepartment of Medicine, Division of Geriatrics and Gerontology, Emory University School of Medicine, Atlanta, GA, USA. \u003csup\u003e5\u003c/sup\u003eAtlanta VA Center for Visual and Neurocognitive Rehabilitation, 2015 Uppergate Dr, Atlanta, GA 30307, USA. \u003csup\u003e6\u003c/sup\u003eDivision of Occupational Therapy, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. \u003csup\u003e7\u003c/sup\u003eCollege of Public Health, Division of Biostatistics, The Ohio State University, Columbus, OH, USA. \u003csup\u003e8\u003c/sup\u003eYale Cancer Center, 333 Cedar St. New Haven, CT 06510, USA.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eSung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u0026ndash;49.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCancer Trends Progress Report [Internet]. Bethesda, MD: National Cancer Institute, NIH, DHHS; 2025 Apr [cited 2024 Nov 15]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://progressreport.cancer.gov/treatment/breast_cancer\u003c/span\u003e\u003cspan address=\"https://progressreport.cancer.gov/treatment/breast_cancer\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEckhoff L, Knoop As J, Mb, Ewertz M. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer. 2015;51(3):292\u0026ndash;300.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011;125(3):767\u0026ndash;74.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLustberg MB, Kuderer NM, Desai A, Bergerot C, Lyman GH. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nat Rev Clin Oncol. 2023;20(8):527\u0026ndash;42.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMezzanotte JN, Grimm M, Shinde NV, Nolan T, Worthen-Chaudhari L, Williams NO, et al. Updates in the Treatment of Chemotherapy-Induced Peripheral Neuropathy. Curr Treat Options Oncol. 2022;23(1):29\u0026ndash;42.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRodwin RL, Siddiq NZ, Ehrlich BE, Lustberg MB. Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions. Front Pain Res. 2022;3:864910.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSong SJ, Min J, Suh SY, Jung SH, Hahn HJ, Im SA, et al. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Support Care Cancer. 2017;25(7):2241\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStubblefield MD, Burstien HJ, Burton AW, Custodio CM, Deng GE, Ho M, et al. NCCN task force report: Management of neuropathy in cancer. J Natl Compr Canc Netw. 2009;7(Suppl5):S1\u0026ndash;26.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWinters-Stone KM, Krasnow SM, Horak FB, Mancini M, Cameron MH, Dieckmann NF, et al. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538). BMC Cancer. 2023;23(1):1087.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology. 2012;291(1\u0026ndash;3):1\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi Y, Lustberg MB, Hu S. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers. 2021;13(4):766.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMonfort S, Worthen-Chaudhari L, Bigelow K, Chaudhari A. Time-Varying Nature of Postural Control during Eyes Closed Quiet Stance. In: Proceedings of the 42nd Annual Meeting of the American Society of Biomechanics (ASB). Rochester, MN; 2018.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMonfort S, Pan X, Patrick R, Singaravelu J, Loprinzi CL, Lustberg MB, et al. Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study. Gait Posture. 2016;48:237\u0026ndash;42.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMonfort S, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton MJ, et al. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Res Treat. 2017;164(1):69\u0026ndash;77.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMonfort S, Pan X, Loprinzi CL, Lustberg MB, Chaudhari AMW. Exploring the Roles of Central and Peripheral Nervous System Function in Gait Stability: Preliminary Insights from Cancer Survivors. Gait Posture. 2019;71:62\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWorthen-Chaudhari LC, Crasta JE, Schnell PM, Lantis K, Martis J, Wilder J et al. Neurologic dance training and home exercise improve motor-cognitive dual-task function similarly, but through potentially different mechanisms, among breast cancer survivors with chemotherapy-induced neuropathy: Initial results of a randomized, controlled clinical trial. J Alzheimer\u0026rsquo;s Dis. 2024;13872877241291440.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang MH. Screening and Examination of Fall Risk in Older Cancer Survivors. Rehabil Oncol. 2019;37(2):E7\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWechsler S, Wood L. The Effect of Chemotherapy on Balance, Gait, and Falls Among Cancer Survivors: A Scoping Review. Rehabil Oncol. 2021;39(1):6\u0026ndash;22.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePatel AV, Friedenreich CM, Moore SC, Hayes SC, Silver JK, Campbell KL, et al. American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control. Med Sci Sports Exerc. 2019;51(11):2391\u0026ndash;402.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStreckmann F, Kneis S, Leifert JA, Baumann FT, Kleber M, Ihorst G, et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann Oncol. 2014;25(2):493\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStreckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, et al. Exercise intervention studies in patients with peripheral neuropathy: A systematic review. Sports Med. 2014;44(9):1289\u0026ndash;304.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVollmers PL, Mundhenke C, Maass N, Bauerschlag D, Kratzenstein S, R\u0026ouml;cken C, et al. Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy. J Cancer Res Clin Oncol. 2018;144(9):1785\u0026ndash;92.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWonders KY, Whisler G, Loy H, Holt B, Bohachek K, Wise R. Ten weeks of home-based exercise attenuates symptoms of chemotherapy-induced peripheral neuropathy in breast cancer patients. Health Psychol Res. 2013;1(3):e28.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZimmer P, Trebing S, Timmers-Trebing U, Schenk A, Paust R, Bloch W, et al. Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. Support Care Cancer. 2018;26(2):615\u0026ndash;24.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWoods JA, Vieira VJ, Keylock KT. Exercise, Inflammation, and Innate Immunity. Immunol Allergy Clin North Am. 2009;29(2):381\u0026ndash;93.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEnglish AW, Wilhelm JC, Ward PJ. Exercise, Neurotrophins, and Axon Regeneration in the PNS. Physiology. 2014;29(6):437\u0026ndash;45.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLudyga S, Gerber M, P\u0026uuml;hse U, Looser VN, Kamijo K. Systematic review and meta-analysis investigating moderators of long-term effects of exercise on cognition in healthy individuals. Nat Hum Behav. 2020;4(6):603\u0026ndash;12.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWorthen-Chaudhari L, Schnell PM, Hackney ME, Lustberg MB. Partnered dance evokes greater intrinsic motivation than home exercise as therapeutic activity for chemotherapy-induced deficits: secondary results of a randomized, controlled clinical trial. Front Psychol. 2024;15:1383143.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHackney ME, Earhart GM. Recommendations for Implementing Tango Classes for Persons with Parkinson Disease. Am J Dance Ther. 2010;32(1):41\u0026ndash;52.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDhami P, Moreno S, DeSouza JFX. New framework for rehabilitation-fusion of cognitive and physical rehabilitation: the hope for dancing. Front Psychol [Internet]. 2015 [cited 2024 Nov 20];5. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://journal.frontiersin.org/article/\u003c/span\u003e\u003cspan address=\"http://journal.frontiersin.org/article/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fpsyg.2014.01478/abstract\u003c/span\u003e\u003cspan address=\"10.3389/fpsyg.2014.01478/abstract\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHackney ME, Byers C, Butler G, Sweeney M, Rossbach L, Bozzorg A. Adapted Tango Improves Mobility, Motor\u0026ndash;Cognitive Function, and Gait but Not Cognition in Older Adults in Independent Living. J Am Geriatr Soc. 2015;63(10):2105\u0026ndash;13.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRehfeld K, L\u0026uuml;ders A, H\u0026ouml;kelmann A, Lessmann V, Kaufmann J, Brigadski T et al. Dance training is superior to repetitive physical exercise in inducing brain plasticity in the elderly. Buchowski MS, editor. PLOS ONE. 2018;13(7):e0196636.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePalo-Bengtsson L, Winblad B, Ekman SL. Social Dancing: a way to support intellectural, emotional and motor functions in persons with dementia. J Psychiatr Ment Health Nurs. 1998;5(6):545\u0026ndash;54.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrown S, Martinez MJ, Parsons LM. The Neural Basis of Human Dance. Cereb Cortex. 2005;16(8):1157\u0026ndash;67.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFederici A, Bellagamba S, Rocchi M. Does dance-based training improve balance in adult and young old subjects? A pilot randomized controlled trial. Aging Clin Exp Res. 2005;17(5):385\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRoss JM, Warlaumont AS, Abney DH, Rigoli LM, Balasubramaniam R. Influence of musical groove on postural sway. J Exp Psychol Hum Percept Perform. 2016;42(3):308\u0026ndash;19.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWorthen-Chaudhari L, Lamantia MT, Monfort SM, Mysiw W, Chaudhari AMW, Lustberg MB. Partnered, adapted argentine tango dance for cancer survivors: A feasibility study and pilot study of efficacy. Clin Biomech. 2019;70:257\u0026ndash;64.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDe Dreu MJ, Van Der Wilk ASD, Poppe E, Kwakkel G, Van Wegen EEH. Rehabilitation, exercise therapy and music in patients with Parkinson\u0026rsquo;s disease: a meta-analysis of the effects of music-based movement therapy on walking ability, balance and quality of life. Parkinsonism Relat Disord. 2012;18:S114\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy. Clin Cancer Res. 2019;25(21):6295\u0026ndash;301.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNilsson U. The Anxiety- and Pain‐Reducing Effects of Music Interventions: A Systematic Review. AORN J. 2008;87(4):780\u0026ndash;807.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNguyen TN, Nilsson S, Hellstr\u0026ouml;m AL, Bengtson A. Music Therapy to Reduce Pain and Anxiety in Children With Cancer Undergoing Lumbar Puncture: A Randomized Clinical Trial. J Pediatr Oncol Nurs. 2010;27(3):146\u0026ndash;55.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u0026oslash;tzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern Med. 2013;158(3):200.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346(jan08 15):e7586\u0026ndash;7586.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHopewell S, Boutron I, Chan AW, Collins GS, De Beyer JA, Hr\u0026oacute;bjartsson A, et al. An update to SPIRIT and CONSORT reporting guidelines to enhance transparency in randomized trials. Nat Med. 2022;28(9):1740\u0026ndash;3.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLantis K, Schnell P, Bland CR, Wilder J, Hock K, Vargo C, et al. Biomechanical effect of neurologic dance training (NDT) for breast cancer survivors with chemotherapy-induced neuropathy: study protocol for a randomized controlled trial and preliminary baseline data. Trials. 2023;24(1):564.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWorthen-Chaudhari L, Monfort S, Bland C, Pan X, Chaudhari A. Characterizing within-subject variability in quantified measures of balance control: a cohort study. Gait Posture. 2018;64:141\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUSCS Data Visualizations [Internet]. [cited 2024 Nov 21]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://gis.cdc.gov/grasp/USCS/DataViz.html\u003c/span\u003e\u003cspan address=\"https://gis.cdc.gov/grasp/USCS/DataViz.html\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMaki BE, Holliday PJ, Topper AK. A Prospective Study of Postural Balance and Risk of Falling in An Ambulatory and Independent Elderly Population. J Gerontol. 1994;49(2):M72\u0026ndash;84.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eReed CA, Chaudhari AM, Worthen-Chaudhari LC, Bigelow KE, Monfort SM. A new perspective on transient characteristics of quiet stance postural control. PLoS ONE. 2020;15(8):e0237246.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePrieto TE, Myklebust JB, Hoffmann RG, Lovett EG, Myklebust BM. Measures of postural steadiness: differences between healthy young and elderly adults. IEEE Trans Biomed Eng. 1996;43(9):956\u0026ndash;66.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRoerdink M, Hlavackova P, Vuillerme N. Center-of-pressure regularity as a marker for attentional investment in postural control: A comparison between sitting and standing postures. Hum Mov Sci. 2011;30(2):203\u0026ndash;12.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSlattery P, Saeri AK, Bragge P. Research co-design in health: a rapid overview of reviews. Health Res Policy Syst. 2020;18(1):17.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHackney ME, McKee K. Community-based adapted tango dancing for individuals with Parkinson\u0026rsquo;s disease and older adults. J Vis Exp. 2015;94:e52066.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcAuley E, Wraith S, Duncan TE. Self-efficacy, perceptions of success, and intrinsic motivation for exercise. J Appl Soc Psychol. 1991;21(2):139\u0026ndash;55.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRyan RM, Koestner R, Deci EL. Ego-involved persistence: When free-choice behavior is not intrinsically motivated. Motiv Emot. 1991;15(3):185\u0026ndash;205.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRyan RM, Deci EL. Self-Determination Theory and the Facilitation of Intrinsic Motivation, Social Development, and Well-Being. Am Psychol. 2000.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBurgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, et al. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. Oncol Ther. 2021;9(2):385\u0026ndash;450.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer. 2018;26(4):1019\u0026ndash;28.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePodsiadlo D, Richardson S. The timed Up \u0026amp; Go: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBlackwood J, Rybicki K. Assessment of Gait Speed and Timed Up and Go Measures as Predictors of Falls in Older Breast Cancer Survivors. Integr Cancer Ther. 2021;20:15347354211006462.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEvans ES, Ketcham CJ, Hibberd JC, Cullen ME, Basiliere JG, Murphy DL. Examination of clinical and laboratory measures of static and dynamic balance in breast cancer survivors. Physiother Theory Pract. 2021;37(11):1199\u0026ndash;209.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMarshall TF, Zipp GP, Battaglia F, Moss R, Bryan S. Chemotherapy-induced-peripheral neuropathy, gait and fall risk in older adults following cancer treatment. J Cancer Res Pract. 2017;4(4):134\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMorishita S, Hirabayashi R, Tsubaki A, Aoki O, Fu JB, Onishi H, et al. Assessment of the Mini-Balance Evaluation Systems Test, Timed Up and Go test, and body sway test between cancer survivors and healthy participants. Clin Biomech. 2019;69:28\u0026ndash;33.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSmith EML, Zanville N, Kanzawa-Lee G, Donohoe C, Bridges C, Loprinzi C, et al. Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire\u0026ndash;Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data. Support Care Cancer. 2019;27(7):2599\u0026ndash;608.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, et al. Validity and Reliability of the US National Cancer Institute\u0026rsquo;s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCleeland CS. Undertreatment of Cancer Pain in Elderly Patients. JAMA. 1998;279(23):1914.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The rapid assessment of fatigue severity in cancer patients: Use of the brief fatigue inventory. Cancer. 1999;85(5):1186\u0026ndash;96.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang MH, Blackwood J, Godoshian M, Pfalzer L. Prevalence of self-reported falls, balance or walking problems in older cancer survivors from Surveillance, Epidemiology and End Results\u0026mdash;Medicare Health Outcomes Survey. J Geriatr Oncol. 2017;8(4):255\u0026ndash;61.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWild B, Eckl A, Herzog W, Niehoff D, Lechner S, Maatouk I, et al. Assessing Generalized Anxiety Disorder in Elderly People Using the GAD-7 and GAD-2 Scales: Results of a Validation Study. Am J Geriatr Psychiatry. 2014;22(10):1029\u0026ndash;38.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi C, Friedman B, Conwell Y, Fiscella K. Validity of the Patient Health Questionnaire 2 (PHQ-2) in identifying major depression in older people. J Am Geriatr Soc. 2007;55(4):596\u0026ndash;602.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoskowitz DS, Young SN. Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology. J Psychiatry Neurosci. 2006;31(1):13\u0026ndash;20.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTsigilis N, Theodosiou A. Temporal Stability of the Intrinsic Motivation Inventory. Percept Mot Skills. 2003;97(1):271\u0026ndash;80.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLamb SE, J\u0026oslash;rstad-Stein EC, Hauer K, Becker C, on behalf of the Prevention of Falls Network Europe and Outcomes Consensus Group. Development of a Common Outcome Data Set for Fall Injury Prevention Trials: The Prevention of Falls Network Europe Consensus. J Am Geriatr Soc. 2005;53(9):1618\u0026ndash;22.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKneis S, Wehrle A, Dalin D, Wiesmeier IK, Lambeck J, Gollhofer A, et al. A new approach to characterize postural deficits in chemotherapy-induced peripheral neuropathy and to analyze postural adaptions after an exercise intervention. BMC Neurol. 2020;20(1):23.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcCrary JM, Goldstein D, Wyld D, Henderson R, Lewis CR, Park SB. Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test. J Cancer Surviv. 2019;13(4):495\u0026ndash;502.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBohannon RW, Crouch R. Minimal clinically important difference for change in 6-minute walk test distance results of adults with pathology: A systematic review. J Eval Clin Pract. 2017;23(2):377\u0026ndash;81.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBut-Hadzic J, Dervisevic M, Karpljuk D, Videmsek M, Dervisevic E, Paravlic A, et al. Six-Minute Walk Distance in Breast Cancer Survivors\u0026mdash;A Systematic Review with Meta-Analysis. Int J Environ Res Public Health. 2021;18(5):2591.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSmith EML. Current Methods for the Assessment and Management of Taxane-Related Neuropathy. Clin J Oncol Nurs. 2013;17(1):22\u0026ndash;34.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStreckmann F, Elter T, Lehmann HC, Baurecht H, Nazarenus T, Oschwald V, et al. Preventive Effect of Neuromuscular Training on Chemotherapy-Induced Neuropathy: A Randomized Clinical Trial. JAMA Intern Med. 2024;184(9):1046\u0026ndash;53.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWołoszyn N, Wiśniowska-Szurlej A, Grzegorczyk J, Kwolek A. The impact of physical exercises with elements of dance movement therapy on the upper limb grip strength and functional performance of elderly wheelchair users living in nursing homes \u0026ndash; a randomized control trial. BMC Geriatr. 2021;21(1):423.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBobos P, Nazari G, Lu Z, MacDermid JC. Measurement Properties of the Hand Grip Strength Assessment: A Systematic Review With Meta-analysis. Arch Phys Med Rehabil. 2020;101(3):553\u0026ndash;65.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDraak TH, Pruppers MH, Van Nes SI, Vanhoutte EK, Bakkers M, Gorson KC, et al. Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar. J Peripher Nerv Syst. 2015;20(3):269\u0026ndash;76.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTrosclair D, Bellar D, Judge LW, Smith J, Mazerat N, Brignac A. Hand-Grip Strength as a Predictor of Muscular Strength and Endurance. J Strength Cond Res. 2011;25:S99.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLaw M, Baptiste S, McColl M, Opzoomer A, Polatajko H, Pollock N. The Canadian Occupational Performance Measure: An Outcome Measure for Occupational Therapy. Can J Occup Ther. 1990;57(2):82\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCarswell A, McColl MA, Baptiste S, Law M, Polatajko H, Pollock N. The Canadian Occupational Performance Measure: A Research and Clinical Literature Review. Can J Occup Ther. 2004;71(4):210\u0026ndash;22.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcColl MA, Pollock N. Measuring occupational performance using a client-centered perspective. Measuring occupational performance. Routledge; 2024. pp. 83\u0026ndash;94.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWressle E, Eeg-Olofsson AM, Marcusson J, Henriksson C. Improved client participation in the rehabilitation process using a client-centred goal formulation structure. J Rehabil Med. 2002;34(1):5\u0026ndash;11.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMirelman A, Weiss A, Buchman AS, Bennett DA, Giladi N, Hausdorff JM. Association Between Performance on Timed Up and Go Subtasks and Mild Cognitive Impairment: Further Insights into the Links Between Cognitive and Motor Function. J Am Geriatr Soc. 2014;62(4):673\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVervoort D, Vuillerme N, Kosse N, Hortob\u0026aacute;gyi T, Lamoth CJC. Multivariate Analyses and Classification of Inertial Sensor Data to Identify Aging Effects on the Timed-Up-and-Go Test. Chen K, editor. PLOS ONE. 2016;11(6):e0155984.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHausdorff JM, Rios DA, Edelberg HK. Gait variability and fall risk in community-living older adults: A 1-year prospective study. Arch Phys Med Rehabil. 2001;82(8):1050\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMaki BE. Gait Changes in Older Adults: Predictors of Falls or Indicators of Fear? J Am Geriatr Soc. 1997;45(3):313\u0026ndash;20.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eToebes MJP, Hoozemans MJM, Furrer R, Dekker J, Van Die\u0026euml;n JH. Local dynamic stability and variability of gait are associated with fall history in elderly subjects. Gait Posture. 2012;36(3):527\u0026ndash;31.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHsieh KL, Trinh L, Sosnoff JJ. Gait variability is altered in cancer survivors with self-reported neuropathy. Gait Posture. 2019;72:206\u0026ndash;10.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWright MJ, Twose DM, Gorter JW. Gait characteristics of children and youth with chemotherapy induced peripheral neuropathy following treatment for acute lymphoblastic leukemia. Gait Posture. 2017;58:139\u0026ndash;45.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGilchrist L, Tanner L. Gait Patterns in Children With Cancer and Vincristine Neuropathy. Pediatr Phys Ther. 2016;28(1):16\u0026ndash;22.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVallabhajosula S, Deaterly CD, Madzima TA. Comparison of forward and backward gait characteristics between those with and without a history of breast cancer. Gait Posture. 2019;74:162\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGaliano-Castillo N, Arroyo-Morales M, Ariza-Garcia A, S\u0026aacute;nchez-Salado C, Fern\u0026aacute;ndez-Lao C, Cantarero-Villanueva I, et al. The six-minute walk test as a measure of health in breast cancer patients. J Aging Phys Activ. 2016;24(4):508\u0026ndash;15.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDingwell JB, Cusumano JP, Sternad D, Cavanagh PR. Slower speeds in patients with diabetic neuropathy lead to improved local dynamic stability of continuous overground walking. J Biomech. 2000;33(10):1269\u0026ndash;77.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDingwell JB, Cavanagh PR. Increased variability of continuous overground walking in neuropathic patients is only indirectly related to sensory loss. Gait Posture. 2001;14(1):1\u0026ndash;10.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSloot LH, Van Schooten KS, Bruijn SM, Kingma H, Pijnappels M, Van Die\u0026euml;n JH. Sensitivity of Local Dynamic Stability of Over-Ground Walking to Balance Impairment Due to Galvanic Vestibular Stimulation. Ann Biomed Eng. 2011;39(5):1563\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVan Schooten KS, Sloot LH, Bruijn SM, Kingma H, Meijer OG, Pijnappels M, et al. Sensitivity of trunk variability and stability measures to balance impairments induced by galvanic vestibular stimulation during gait. Gait Posture. 2011;33(4):656\u0026ndash;60.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWiles TM, Kim SK, Stergiou N, Likens AD. Pattern analysis using lower body human walking data to identify the gaitprint. Comput Struct Biotechnol J. 2024;24:281\u0026ndash;91.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGlover N, WIlder J, Hackney M, Lustberg M, Worthen-Chaudhari L. Case Study in Chemotherapy-Induced Neuropathy: Tango Dance Improved Over-Ground Local Gait Stability. Arch Phys Med Rehabil. 2023;104(3):e16.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChaudhari A, Monfort S, Lamantia M, Lustberg M, Worthen-Chaudhari L. Effect of an Argentine Tango Intervention on Gait Variability in Cancer Survivors: 2413 Board# 4 June 2 9. Med Sci Sports Exerc. 2017;49(5S):675\u0026ndash;675.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKneis S, Wehrle A, Freyler K, Lehmann K, Rudolphi B, Hildenbrand B, et al. Balance impairments and neuromuscular changes in breast cancer patients with chemotherapy-induced peripheral neuropathy. Clin Neurophysiol. 2016;127(2):1481\u0026ndash;90.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi Q, Wang X, Li X, He X, Wan Q, Yin J, et al. Obtaining High-Quality Blood Specimens for Downstream Applications: A Review of Current Knowledge and Best Practices. Biopreservation Biobanking. 2018;16(6):411\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLohmann AE, Dowling RJO, Ennis M, Amir E, Elser C, Brezden-Masley C, et al. Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. JNCI Cancer Spectr. 2018;2(2):pky028.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDevasahayam AJ, Kelly LP, Williams JB, Moore CS, Ploughman M. Fitness Shifts the Balance of BDNF and IL-6 from Inflammation to Repair among People with Progressive Multiple Sclerosis. Biomolecules. 2021;11(4):504.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGejl AK, Enevold C, Bugge A, Andersen MS, Nielsen CH, Andersen LB. Associations between serum and plasma brain-derived neurotrophic factor and influence of storage time and centrifugation strategy. Sci Rep. 2019;9(1):9655.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWharton W, Jeong L, Ni L, Bay AA, Shin RJ, McCullough LE, et al. A Pilot randomized clinical trial of adapted tango to improve cognition and psychosocial function in African American women with family history of Alzheimer\u0026rsquo;s disease (ACT trial). Cereb Circ - Cogn Behav. 2021;2:100018.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBenashley L, Bucy A, Wertheim B. Paclitaxel Treatment Effects on Neurofilament Light Chain (NF-L), a Possible Biomarker of Chemotherapy-Induced Peripheral Neuropathy (CIPN). Cancer Epidemiol Biomarkers Prev. 2022;31:1510\u0026ndash;1.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBurgess BL, Cho E, Honigberg L. Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin. Sci Rep [Internet]. 2022 Sep 16 [cited 2025 May 1];12(1). Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.nature.com/articles/s41598-022-18716-5\u003c/span\u003e\u003cspan address=\"https://www.nature.com/articles/s41598-022-18716-5\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKleckner IR, Jusko TA, Culakova E, Chung K, Kleckner AS, Asare M, et al. Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy. Breast Cancer Res Treat. 2021;189(2):521\u0026ndash;32.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCrasta JE, Thaut MH, Anderson CW, Davies PL, Gavin WJ. Auditory priming improves neural synchronization in auditory-motor entrainment. Neuropsychologia. 2018;117:102\u0026ndash;12.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWorthen-Chaudhari L, McGonigal J, Logan K, Bockbrader MA, Yeates KO, Mysiw WJ. Reducing concussion symptoms among teenage youth: Evaluation of a mobile health app. Brain Inj. 2017.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":true,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"trials","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"trls","sideBox":"Learn more about [Trials](http://trialsjournal.biomedcentral.com/)","snPcode":"13063","submissionUrl":"https://www.editorialmanager.com/trls","title":"Trials","twitterHandle":"MedicalEvidence","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"chemotherapy-induced neuropathy, oncology, neurorehabilitation, music, dance, biomechanics","lastPublishedDoi":"10.21203/rs.3.rs-6814353/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6814353/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cb\u003eBackground\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cspan type=\"SmallCaps\" class=\"SmallCaps\" name=\"Emphasis\"\u003eBreast cancer (BC) is among the most common forms of cancer, particularly among women. Chemotherapies that are most effective in treating BC are known to cause chemotherapy-induced neuropathy (CIN), thus leaving survivors with sensory deficits including pain, numbness, and tingling in the extremities; functional deficits such as impaired neuromotor control and motor-cognitive integration; reduced quality of life; and increased fall risk. Current pharmacologic treatments show limited efficacy and create additional unwanted side effects. In contrast, physical activity (PA) has emerged as a promising nonpharmacologic candidate for managing CIN symptoms. The purpose of this trial is to evaluate the effect of Adapted Argentine Tango (Tango) as a potential treatment for CIN. Toward this end, we will assess the intervention effect of Tango vs. the standard of care (SOC) on patient-reported outcomes of sensation, clinically-relevant measures of function, and potential mechanisms of action. We hypothesize that 4 weeks of Tango practice will improve sensation and function more than SOC among BC survivors with CIN and demonstrated balance dysfunction.\u003c/span\u003e \u003c/p\u003e\u003cp\u003e\u003cb\u003eMethods\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cspan type=\"SmallCaps\" class=\"SmallCaps\" name=\"Emphasis\"\u003eIn a multi-center, prospective, randomized controlled clinical trial, participants are randomly assigned (1:1 ratio) to the Tango experimental or the SOC active control arms. Primary outcomes are measured from baseline to after 4 weeks of intervention in patient-reported outcomes (PROs) of sensation and dual-task function. Secondary outcomes include additional PROs, such as fatigue, and clinical measures of interest after 4 and 8 weeks of intervention and 1 month following intervention completion. Exploratory measures include postural control, gait stability, cognitive load, and blood-based biomarker concentrations. Linear mixed models will be used to model changes in PROs and function. The primary estimand will be the difference in mean change in primary outcomes from baseline to week 4 between treatment groups.\u003c/span\u003e \u003c/p\u003e\u003cp\u003e\u003cb\u003eDiscussion\u003c/b\u003e\u003c/p\u003e \u003cp\u003e\u003cspan type=\"SmallCaps\" class=\"SmallCaps\" name=\"Emphasis\"\u003e The scientific premise of this study is that Tango stands to improve CIN symptoms significantly more than the current standard of care by combining PA with auditory-motor entrainment and social engagement. Our findings may lead to a safe non-pharmacologic intervention that improves CIN-related deficits.\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eTrial Registration\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cspan type=\"SmallCaps\" class=\"SmallCaps\" name=\"Emphasis\"\u003eThis trial was first posted on 12/27/24 at ClinicalTrials.gov under the identifier NCT06749210.\u003c/span\u003e \u003c/p\u003e","manuscriptTitle":"Dance-based avenues to advance nonpharmacologic treatment of chemotherapy effects (DAANCE): Study protocol for a multi-center, randomized controlled trial","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-07-07 08:23:39","doi":"10.21203/rs.3.rs-6814353/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Major revision","date":"2025-07-30T17:02:47+00:00","index":"","fulltext":""},{"type":"reviewerAgreed","content":"","date":"2025-07-07T12:18:35+00:00","index":0,"fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-07-03T10:39:45+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-06-12T11:31:40+00:00","index":"","fulltext":""},{"type":"submitted","content":"Trials","date":"2025-06-03T16:19:48+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"trials","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"trls","sideBox":"Learn more about [Trials](http://trialsjournal.biomedcentral.com/)","snPcode":"13063","submissionUrl":"https://www.editorialmanager.com/trls","title":"Trials","twitterHandle":"MedicalEvidence","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"7647d5d8-0b12-43c1-9ce9-b002d3b9c2eb","owner":[],"postedDate":"July 7th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2026-02-23T16:03:00+00:00","versionOfRecord":{"articleIdentity":"rs-6814353","link":"https://doi.org/10.1186/s13063-026-09486-w","journal":{"identity":"trials","isVorOnly":false,"title":"Trials"},"publishedOn":"2026-02-21 15:59:31","publishedOnDateReadable":"February 21st, 2026"},"versionCreatedAt":"2025-07-07 08:23:39","video":"","vorDoi":"10.1186/s13063-026-09486-w","vorDoiUrl":"https://doi.org/10.1186/s13063-026-09486-w","workflowStages":[]},"version":"v1","identity":"rs-6814353","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6814353","identity":"rs-6814353","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}